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                                                              ABSTRACT 
            The era of highly active antiretroviral therapy (HAART) has controlled AIDS and 
its related disorders considerably; however, the prevalence of HIV-1-associated 
neurocognitive disorders (HAND) has been on the rise in the post-HAART era.  In view 
of these developments, we investigated whether a HAART drug combination of 3’-
Azido-2’, 3’-deoxythymidine (AZT) and Indinavir (IDV) can alter the functionality of the 
blood-brain barrier (BBB) endothelial cells, thereby exacerbating the condition. Viability 
of hCMEC/D3 cells (in vitro model of BBB) that were exposed to the drugs was 
significantly reduced after a 72 hr treatment, in a dose-dependent manner. Reactive 
oxygen species (ROS) were highly elevated after the exposure, indicating that 
mechanisms that induce oxidative stress were involved. Measures of oxidative stress such 
as glutathione (GSH) and malondialdehyde (MDA) were found to be altered in the 
treated groups. Loss of mitochondrial membrane potential (ΔΨm) assessed with 
fluorescent microscopy and decreased levels of ATP indicated that cytoxicity was 
mediated through mitochondrial dysfunction. Furthermore, AZT + IDV treatment caused 
apoptosis in endothelial cells as assessed by the expression of cytochrome c and 
procaspase-3 proteins. In vivo experiments with HIV-1 transgenic animal treated with 
AZT+IDV showed decrease in GSH in the BBB and brain and increase in MDA levels in 
the BBB. Thiol antioxidant N-acetylcysteine amide (NACA) reversed some of the pro-
oxidant effects of AZT+IDV in both invitro and invivo studies. 
            Results from our studies indicate that the AZT + IDV combination can affect the 
BBB and may play a role in contributing to neurocognitive disorders in HIV-1 infected 
individuals treated with HAART drugs.    
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                                                  1.  INTRODUCTION 
            Human immunodeficiency virus type 1 (HIV-1) is a lentivirus (a member of 
the retrovirus family) that causes acquired immunodeficiency syndrome (AIDS), a 
condition in humans in which the immune system begins to fail, leading to life-
threatening opportunistic infections. HIV-1 infection has also been identified for its 
ability to target the nervous tissues. Infection of the nervous system with HIV can lead to 
a syndrome of neurological dysfunction currently termed as HIV-associated 
neurocognitive disorders; HAND (Antinori et al., 2007). HAND is a collective term used 
to denote the neurological complications of AIDS, consisting of the triad of cognitive, 
behavior, and motor dysfunction (McArthur et al., 2004). HAND develops in about one 
third of patients who progress to AIDS. The precise mechanisms of pathogenesis 
involved in HIV induced central nervous system injury are still not completely 
understood. 
            The blood- brain barrier (BBB), a selective interface between blood and the 
central nervous system, regulates the transport of substances from blood to brain and 
brain to blood (Banks et al., 2005). The disruption of this layer has been implicated in 
number of neurocognitive disorders like Alzheimer’s and Parkinson’s disease (Zipser et 
al., 2007; Power et al., 1993).  A mild to normal grade disruption has been found in HIV 
patients with neurocognitive disorders (Power et al., 1993). Recent studies have reported 
that viral proteins like glyco-protein 120 (gp 120) and transregulatory (Tat) protein can 
alter the  endothelial function and disrupt the blood brain barrier, both in vitro and in 




2010). These alterations can play critical roles in the signaling pathways that lead to 
upregulation of inflammatory genes in the BBB and accelerate neurodegeneration.  
            Introduction of highly active antiretroviral therapy (HAART), the combination of 
two or more classes of antiretroviral drugs, has led to a considerable decline in HIV 
disease progression rates and related opportunistic infections.  Despite these significant 
improvements in health conditions, mild cognitive impairment in HIV -infected 
individuals seems to be on the rise and still remains a public health concern in the 
HAART era (Sacktor et al., 2002).  Recent studies have shown that neurocognition 
improved significantly following discontinuation of HAART in subjects with preserved 
immune function (Robertson et al., 2010). HAART regimens have been recognized as 
leading to mitochondrial toxicity and are associated with cardiac, hepatic, hematologic, 
and myopathic morbidity (Carr et al., 1999). Numerous mechanisms have been proposed 
to explain the deleterious impact of HAART drugs, including mitochondrial DNA 
depletion, impaired mitochondrial replication via inhibition of the mitochondrial DNA 
polymerase gamma (POLγ), and subsequent increase in reactive oxygen species and 
oxidative stress (Lewis et al., 2003).  
             The above discussed research, concerning the effects of HAART drugs in various 
metabolic disorders raises doubt about the possible impact of antiretroviral therapy on   
the BBB and neurocognition in HAART-treated HIV patients. To the best of our 
knowledge, no known study has been done to evaluate the effect of HAART drugs on the 
human blood-brain barrier and the mechanism involved in this effect. In order to address 
this concern, we hypothesized that HAART drugs may cause endothelial dysfunction in 
the BBB, thereby exacerbating HIV-1- associated neurocognitive disorders.  In order to 
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test our hypothesis we evaluated the effect of the combination of 3’-Azido-2’, 3’-
deoxythymidine (AZT), and Indinavir (IDV), (a commonly recommended HAART 
regimen) on various oxidative stress parameters, as well mitochondrial dysfunction in 
blood-brain barrier endothelial cells (Yeni et al., 2004). In addition to this, toxicity of 
HIV proteins, HAART toxicity appears to be related through a common phenomenon of 
oxidative stress. The possible involvement of oxidative stress suggests the use of 
antioxidants in suppressing harmful effects and protecting the BBB. Recently, a new low 
molecular thiol antioxidant, N-acetylcysteine amide (NACA), with the ability to cross the 
BBB has been effective in protecting cells from viral proteins in in vitro and in vivo 
studies in our lab (Price et.al., 2006). So we investigated the role of oxidative stress in 
viral proteins and HAART drugs induced toxicity in the BBB of HIV-1 transgenic mice. 
Concomitantly, we explored the antioxidant effect of NACA in reversing the oxidative 













                                         2.  REVIEW OF LITERATURE 
2.1. GLOBAL STATISTICS ON HIV 
            In 1981, the first cases of acquired immunodeficiency syndrome (AIDS) were 
reported to the Centers for Disease Control and Prevention (CDC). Since that time, the 
HIV epidemic has expanded to become one of the greatest public health challenges, both 
nationally and globally. There are estimated to be around 33.2 million people living with 
HIV or AIDS worldwide today and around 2.5 million more people are newly infected 
with HIV every year. Of the 2.5 million people newly infected with HIV each year, 50% 
of them are under the age of 25 years. Around 22.5 million people who are currently 
infected with HIV or AIDS are living in Africa, and more than one million people were 
living with AIDS in USA. A total of 25 million people have died from AIDS since the 
year 1981 and it is estimated that more than half a million have died in the U.S alone 
(Woods et al., 2009). 
2.2. STRUCTURE OF HIV 
            HIV is an enveloped RNA virus whose basic structure consists of an outer bilayer 
of lipid and glycoprotein and an inner core containing two single RNA strands bound 
together by a gag-derived protein, p24. The outer membrane of HIV contains specific 
structural elements that play important roles in infectivity and disease progression. The 
most important of these is the viral envelope glycoprotein 120 (gp120), which is 
necessary for HIV’s interaction with host cell receptors on cells, including CD4+ 
lymphocytes, macrophages, and monocytes. Gp120 is closely associated with the 
envelope transmembrane viral protein, gp41, which is involved in viral–cell membrane 
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fusion. Both gp41 and gp120 are essential for infectivity. Gp120 interacts with the CD4+ 
receptor on the surface of susceptible cells. However, gp120 attachment also requires the 
presence of chemokine co-receptors, such as CXCR4 or CCR5, which facilitate the 
process of cell binding and entry (Gonda, 1988). 
2.3. HIV-1-ASSOCIATED NEUROCOGNTIVE DISORDERS (HAND) 
            HIV enters the CNS early in the course of infection, and the virus resides 
primarily in microglia and macrophages. However, infection of these cells may not be 
sufficient to initiate neurodegeneration (Gartner et al., 2000). It has been proposed that 
factors associated with advanced HIV infection in the periphery (non-CNS) are important 
triggers for events leading to neurocognitive disorders (Kaul et al., 2001). The clinical 
manifestations of CNS disorders in HIV/AIDS include depression and all degrees of 
cognitive impairment collectively termed as HIV-1-associated neurocognitive disorder 
(HAND). HAND is characterized by a triad of cognitive, behavioral, and motor 
dysfunctions (McArthur, 2004). For milder forms of HAND, difficulties in concentration, 
attention, and memory may be present although the neurologic examination is 
unremarkable. Affected individuals are easily distracted, lose their train of thought, and 
require repeated prompting. Activities of daily living may take longer and become more 
laborious.  
            More severe forms of HAND, such as HIV- associated dementia, are seen in 
untreated HIV individuals. Cognitive and motor dysfunctions are more pronounced in 
these individuals, and the assistance of a caregiver is required to maintain activities of 
daily living. The most commonly observed symptoms include delayed speech output with 
long pauses between words, poor thought and emotional content characterized by lack of 
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spontaneity, and social withdrawal that is often mistakenly diagnosed as severe 
depression. Gait abnormalities and a reduction in motor movements are observed (Woods 
et al., 2009).  
            To date, the four possible mechanisms that are supportive of viral entry into the 
CNS and are currently under investigation include: the transmission of virus in infected 
macrophages (the Trojan horse model), direct infection of the blood-brain barrier (BBB) 
by HIV; transcytosis of HIV; and BBB disruption (Piacentini et al., 2005). This neuro 
invasion in turn elicits a series of neuroinflammatory responses, resulting in neurologic 
dysfunctions in a significant number of individuals with AIDS. This is characterized by 
BBB disruption, leukocyte infiltration into the CNS, formation of microglia nodules and 
multinucleated giant cells, astrocyte activation and eventual damage and/or loss of 
neurons (Xu et al., 2005). To date the mechanisms leading to HAND in AIDS patients are 
not fully understood; however, it is thought that activated macrophage, microglia, and 
astrocytes produce chemokines and cytokines that in conjunction with secreted viral 
proteins may damage the  BBB and leading to increased permeability and  neuronal 
demise (Giulian et al., 1990; Bellizzi et al., 2006; Rumbaugh and Nath, 2006). 
2.4. BLOOD-BRAIN BARRIER 
            The BBB is crucial in HIV infection of the CNS (Gartener et al., 2000).  The BBB 
is an endothelial barrier present in capillaries that innervate the brain. The BBB is 
selective barrier which impedes entry from the blood to the brain of virtually all 
molecules, except those that are small and lipophilic. The BBB endothelial cells differ 
from endothelial cells in the rest of the body by the absence of fenestrations, more 
extensive tight junctions (TJs), and sparse pinocytic vesicular transport. Endothelial cell 
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tight junctions limit the paracellular flux of hydrophilic molecules across the BBB. In 
contrast, small lipophilic substances such as O2  and CO2 diffuse freely across plasma 
membranes along their concentration gradient (Grieb et al., 1985). Nutrients including 
glucose and amino acids enter the brain via transporters, whereas receptor-mediated 
endocytosis mediates the uptake of larger molecules including insulin, leptin, and iron 
transferrin (Pardridge et al., 1985; Zhang et al., 2001). In addition to endothelial cells, the 
BBB is composed of the capillary basement membrane (BM), astrocyte end-feet 
ensheathing the vessels and pericytes (PCs) embedded within the BM. The TJ consists of 
three integral membrane proteins, namely, claudin, occludin, and junction adhesion 
molecules, and a number of cytoplasmic accessory proteins including ZO-1, ZO-2, ZO-3, 
cingulin, and others.  Claudins-1 and -2 are 22 kDa phosphoprotein and have four 
transmembrane domains. Claudins bind to claudins on adjacent endothelial cells to form 
a primary seal of the TJ (Furuse et al., 1999). A carboxy terminal of claudins binds to 
cytoplasmic proteins including ZO-1, ZO-2, and ZO-3. Occludin is a 65-kDa 
phosphoprotein, significantly larger than claudin.  Occludin has four transmembrane 
domains, a long COOH-terminal cytoplasmic domain, and a short NH2-terminal 
cytoplasmic domain. The two extracellular loops of occludin and claudin, originating 
from neighboring cells, form the paracellular barrier of TJ. The cytoplasmic domain of 
occludin is directly associated with ZO protein. Cytoplasmic proteins involved in TJ 
formation include zonula occludens proteins (ZO-1, ZO-2, and ZO-3), cingulin, 7H6, and 
several others. Importantly, actin, the primary cytoskeleton protein, binds to COOH-
terminal of ZO-1 and ZO-2, and this complex cross-links transmembrane elements and 
thus provides structural support to the endothelial cells. In pathologic conditions, a 
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number of chemical mediators are released that increase BBB permeability. Several of 
these mediators of BBB opening have been studied in both in vivo and in vitro 
experiments and include glutamate, aspartate, taurine, ATP, endothelin-1, NO, MIP-2, 
tumor necrosis factor-a (TNF-α), and IL-β, which are produced by astrocytes . Other 
agents reported to increase BBB permeability are bradykinin, 5HT, histamine, thrombin, 
UTP, UMP, substance P, quinolinic acid, platelet activating factor, and free radicals 
(Abbott, 2002; Annunziata et al., 1998; Pan et al., 2001; Stastny et al., 2000). 
                      
 
                          
Figure 2.1. Schematic representation of protein interactions at tight junctions  
 
             Histological studies of specimens from HIV-1-infected humans and simian 
immunodeficiency virus (SIV)-infected rhesus macaques show that lymphocytes and 
monocytes migrate into the brain (Prospero-Garcia et al., 1996; Kalams et.al., 1995). 
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However, the relevance of CNS-invading lymphocytes in HAND is not clear. It has also 
been suggested that the inflammatory cytokine tumour-necrosis factor-a (TNF-) opens a 
paracellular route for HIV-1 across the BBB (Fiala et al., 1997). These findings indicate 
that one reason why HAND rarely occurs before the onset of advanced HIV disease is 
that a scathing cycle of immune dysregulation and BBB dysfunction is required to 
achieve sufficient entry of infected or activated immune cells into the brain to cause 
neuronal injury. Alterations of the BBB have been observed in transgenic mice 
expressing the HIV envelope protein gp120 in a form that circulates in plasma, 
suggesting that circulating virus or envelope proteins may also cause BBB dysfunction 
during the viremic phase of primary infection (Toneatto et al., 1999). 
2.5. OXIDATIVE STRESS IN BBB DYSFUNCTION 
            Free radicals are compounds possessing an unpaired electron, which renders them 
highly reactive and capable of causing oxidative damage to all the major macro-
molecules in cells, including lipids, proteins and nucleic acids (Zoccal et al., 2000). A 
major family of free radicals is the reactive oxygen species (ROS), derived metabolically 
from molecular oxygen via superoxide anions (O2-). Oxidative attack on proteins results 
in the formation of protein carbonyls, often with the loss of functionality of the parent 
protein. Polyunsaturated fatty acids, which are major components of cell membranes, can 
also undergo free radical attack, producing lipid peroxidation products like 
malondialdehyde (MDA) and 4-hydroxynonenal (Halliwell et al., 1997). Under normal 
circumstances, the body is protected from such damage by a careful balance between pro-
oxidants and cellular antioxidants like glutathione. Any imbalance between the pro-
oxidants and antioxidants results in a condition called oxidative stress. 
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            Under physiological conditions, the integrity of the BBB is shielded from 
oxidative stress because the brain endothelial cells have high cellular levels of 
antioxidants such as GSH, superoxide dismutase (SOD), catalase (CAT) and glutathione 
peroxidase (GPx).  These enzymes protect the cells from free radicals and peroxidative 
damage (Price et al., 2006). On the other hand, BBB is highly susceptible to oxidative 
damage due to the presence of poly unsaturated fatty acids (PUFA’s).  These fatty acids 
are easily peroxidizable leading to lipid peroxidation metabolites like MDA. Free radical 
production and the resulting oxidative stress, along with circulating inflammatory 
chemokines, play a key role in HAND (Agarwal et. al., 1999). 
             Viral proteins, gp 120 and Tat have been shown to cause oxidative stress in 
endothelial cells. The mechanism by which HIV-1 proteins induce oxidative stress is not 
completely known. One proposed mechanism is that HIV-1 induced neurotoxicity may be 
due to an increased production of ROS by HIV-1 proteins (gp120 and Tat). The 
pathogenesis of HIV-1 infection has implicated increased levels of ROS. HIV-infected 
individuals have abnormally low levels of antioxidants, such as glutathione (GSH), the 
major intracellular defense against the production of ROS. Additionally, a reduction in 
GSH levels, accompanied by elevated levels of malondialdehyde (MDA), a reflection of 
increased levels of lipid peroxidation, has been reported in HIV-1 infected patients 
(Sonneberg et al., 1988). 
The HIV-1 envelope glycoprotein (gp120) and transregulatory protein (Tat) of 
HIV-1 are neurotoxic and cytotoxic and have been implicated in the development of 
HAND. They are known to cause oxidative stress and have been associated with 
disruption of the BBB (Annuziata et al., 2003). Recently, it has been shown that there is 
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some evidence that binding of gp120 or Tat protein to brain endothelial cells may cause 
many of the changes seen in the BBB. For example, one study found a significant 
increase in permeability (up to 47%) in cultured endothelial cells after exposure to gp120 
(Cioni et al., 2002). Another study confirmed that gp120 is capable of changing and 
activating the vascular component of the BBB in vivo (Tonneato et al., 1999). Another 
study of HIV-1 Tat protein demonstrated that exposure of endothelial cells to HIV-1 Tat 
protein resulted in a dose-dependent increase in oxidative stress and a decrease in 
intracellular GSH (Toborek et al., 2003). GSH, which is an important intracellular non-
protein thiol compound in the mammalian cells, has a pivotal role in the maintenance of 
membrane integrity. It may also play an important role in the proper functioning of the 
BBB (Agarwal et. al., 1999). Although brain endothelial cells possess high intracellular 
levels of antioxidative defense mechanisms, such as GSH, GSH peroxidase, and catalase, 
exposure to toxins and drugs may render the BBB susceptible to toxic damage and alter 
its specific functions.  
  Both gp120 and Tat are able to induce apoptosis of cultured neurons and can 
render neurons vulnerable to excitoxicity and oxidative stress (Corasaniti et al, 2001). 
Other viral proteins, Nef, Vpr, and protease, are also suggested as sources of oxidative 
stress, as well as being disruptive and causing change in the mitochondrial 
transmembrane potential (Aksenova et al., 2005). Most researchers believe that the least 
instigation of apoptosis by oxidative stress is during HAND, although other factors may 
also play key or supportive roles. Pro-apoptotic conditions related to oxidative stress 
include: depletion of Bcl-2, (an anti-apoptotic/antioxidant protein), decrease in apoptosis 
in cells infected with HIV (even though antioxidants are provided), and secretion of pro-
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apoptotic/pro-oxidant cytokines (molecular signalers) from macrophages (Lipton et al., 
1995)  
It has been found that the death of neurons in a rat cortex neuronal culture, 
mediated by gp120, was due to nitric oxide (NO) production (Dawson et al., 1993). NO, 
which is synthesized by vascular endothelial cells, is a very strong vasodilatory 
substance. NO also helps to modulate signaling in intercellular and intracellular 
communication for BBB permeability. In addition, NO regulates ion channels in cells, 
neurotransmissions, and cytotoxicity. NO may not be the only toxin, or even the only free 
radical, associated with HAND. Vague schematics of general pathways for infection are 
proposed, however.  It is commonly thought that gp120 plays a role in the infection of the 
BBB’s endothelial cells, creating an environment in which there is greater nitric oxide 
synthase (NOS) production. Once the NOS produces more NO, the NO could cause the 
breakdown of the BBB’s endothelial cells, rendering it ineffective in its usual functions 
(Dawson et al., 1993). Previous research has also demonstrated that oxidative stress was 
induced in brain endothelial cells in vitro and in vivo, when exposed to the HIV-1   
proteins gp 120 and Tat protein depleted intracellular GSH, increased lipid peroxidation, 
and reduced antioxidant enzyme levels (catalase, GPx, glutathione reductase). CD-1 
mice, injected with these proteins (gp120 + Tat) also decreased the expression of tight 
junction proteins ZO-1, ZO-2, Occludin, and Claudin-5 (Banerjee et al., 2010). 
2.6. HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)  
       During the last twenty years, major progress has been made in the understanding 
and treatment of human immunodeficiency virus (HIV) infection. Different classes of 
antiretroviral agents are approved for the treatment of HIV-infection (Table 2.1). These 
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substances could be divided into three classes, based on their mechanisms of action 
(Clercq et al., 2005). 
 Reverse transcriptase inhibitors (RTIs): This class of drugs targets construction of viral 
DNA by inhibiting activity of reverse transcriptase. There are two subtypes of RTIs with 
different mechanisms of action: nucleoside-analogue RTIs (NRTIs) are incorporated into 
the viral DNA leading to chain termination, while non-nucleoside-analogue RTIs 
(NNRTIs) distort the binding potential of the reverse transcriptase enzyme. RTIs come in 
three forms: 
 Nucleoside analog reverse transcriptase inhibitors (NARTIs or NRTIs) 
 Nucleotide analog reverse transcriptase inhibitors (NtARTIs or NtRTIs) 
 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
            The mode of action of NRTIs and NtRTIs is essentially the same; they are 
analogues of the naturally occurring deoxynucleotides needed to synthesize the viral 
DNA and they compete with the natural deoxynucleotides for incorporation into the 
growing viral DNA chain. However, unlike the natural deoxynucleotides substrates, 
NRTIs and NtRTIs lack a 3'-hydroxyl group on the deoxyribose moiety. As a result, 
following incorporation of an NRTI or an NtRTI, the next incoming deoxynucleotide 
cannot form the next 5'-3' phosphodiester bond needed to extend the DNA chain. Thus, 
when an NRTI or NtRTI is incorporated, viral DNA synthesis is halted, a process known 
as chain termination (Jochmans et al., 2008). All NRTIs and NtRTIs are classified 
as competitive substrate inhibitors. In contrast; NNRTIs have a completely different 
mode of action. NNRTIs block reverse transcriptase by binding at a different site on the 
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enzyme, compared to NRTIs and NtRTIs. NNRTIs are not incorporated into the viral 
DNA but instead inhibit the movement of protein domains of reverse transcriptase that 
are needed to carry out the process of DNA synthesis. NNRTIs are therefore classified 
as non-competitive inhibitors of reverse transcriptase.  
Protease inhibitors (PIs): HIV-1 protease is a complex enzyme composed of two 
identical halves (ie, a symmetrical dimer) with an active site located at the base of the 
cleft. It is responsible for the cleavage of the large viral precursor polypeptide chains into 
smaller, functional proteins, thus allowing maturation of the HIV virion. This process 
takes place in the final stages of the HIV life cycle. Inhibition of the protease enzyme 
results in the release of structurally disorganized and noninfectious viral particles. 
Protease inhibitors target viral assembly by inhibiting the activity of protease, an enzyme 
used by HIV to cleave nascent proteins for final assembly of new virons. HIV PI’s target 
the peptide linkages in the gag and gag-pol polyproteins which must be cleaved by 
protease (Monini et al., 2003). All approved PI’s contain a hydroxyethylene bond instead 
of a normal peptide bond. The hydroxyethylene bond makes PI’s non-scissile substrate 
analogs for HIV protease (Figure 2.2). There are 10 PIs currently approved for clinical 
use. Drug interactions are important considerations with the use of PIs. Protease 
inhibitors are substrates for the cytochrome P450 system (primarily CYP3A4) and are 
themselves, to varying degrees, inhibitors of this system, with ritonavir being the most 
potent inhibitor. 
            Some PIs, such as lopinavir and tipranavir, are also inducers of CYP3A4. This 
leads to a significant number of interactions with drugs that are inducers, inhibitors, or 
substrates of this system (Block et al., 2004). 
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Fusion inhibitors: These drugs block HIV from fusing with a cell's membrane to enter 
and infect it. 
 
Table 2.1. Approved HAART drugs  
Protease  
Inhibitors 
NRTIs NNRTIs Mixed Class  
Mprenavir Abacavir Delavirdine enfuvirtide ( fusion inhibitor) 
Atazanavir Didanosine (ddI) Efavirenz maraviroc (CCR5 antagonist) 
Darunavir  Emtricitabine (FTC) Etravirine raltegravir (integrase inhibitor) 
Fosamprenavir Lamivudine (3TC) Nevirapine 
Indinavir Stavudine (d4T) Delavirdine 
Lopinavir/ritonavir Zidovudine (AZT) 
Nelfinavir Zalcitabine (ddC) 
 
 
Integrase inhibitors: These drugs inhibit the enzyme integrase, which is responsible for 
integration of viral DNA into the DNA of the infected cell. There are several integrase 
inhibitors currently under clinical trial but none are commercially available. 
         Current national guidelines for antiretroviral therapy recommend the use of 
combinations of different classes of antiretroviral agents. These therapeutic regimes, 
called highly active antiretroviral therapy (HAART), usually consist of 2 NRTIs 
combined with a PI or a NNRTI (Clercq et al., 2005). Alternative regimes include 3 
NRTIs. HAART is now the standard of care for HIV-therapy and has led to substantial 






Figure 2.2.  Mechanism of action of protease inhibitors.  
 
            Since HAART is unlikely to eradicate HIV-1, antiviral therapy may be required 
for a lifetime, leading to an increase in attention on the long term safety of HAART.   
Previously, according to the International U.S. AIDS Panel, no known adverse effects 
have been reported in patients treated with a combination of 3’-azido-2’, 3’-
deoxythymidine (AZT or Zidovudine), and indinavir (IDV) -one of the most common 
therapeutic regimens recommended in HAART (Yeni et al., 2004). AZT belongs to the 
class of NRTIs, and structurally resembles a thymidine (a nucleoside analog) whereas 
IDV belongs to protease inhibitor family (Figure 2.3).  However, several toxicities related 
to these drugs have been recently reported.  As the AZT+IDV combination is one of the 
common regimens in HAART, our current study was performed utilizing a combination 
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Figure 2.3.  Structure of (A) 3’-azido-2’, 3’-deoxythymidine (B) Indinavir. 
 
 2.7. NEUROCOGNITIVE DISORDERS IN HAART ERA 
            Since its introduction in 1996, HAART has drastically improved the life 
expectancy of those living with HIV. Antiretroviral therapy has led to long-term survival 
for HIV-infected individuals. Thus, the number of HIV-infected persons has increased 
along with the proportion of those who are considered “older”. While the incidence of a 
severe form of HAND appears to have decreased since the introduction of HAART, the 
prevalence of HAND appears to be on the rise. Unfortunately, it is not at all clear that 
HAART provides long-term protection from HAND. In recent years, the incidence of 
HAND as an AIDS-defining illness has actually increased and recent studies have 
estimated that the prevalence of HAND is unchanged or escalating, even in populations 
with extensive use of HAART. The proportion of new cases of HAND demonstrating a 
CD4 count greater than 200 is also increasing in HAART patients (Sacktor et al 2001).  
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            The associated toxicity of long-term antiretroviral therapy includes the risk of 
developing central obesity, dyslipidemia, and insulin resistance (Behrens et al., 1999). It 
is well known that vascular endothelial dysfunction is a common phenomenon in 
HAART- treated patients, and this known association between these vascular risk factors 
and dementia, suggests that long-term HAART use may actually contribute to the risk of 
acquiring HAND (Whitmer et al. 2005). Metabolic derangement observed in HAART-
treated patients that might contribute to HAND risk is the effect of nucleoside reverse 
transcriptase inhibitors (NRTIs) on mitochondria. HAART regimens that include NRTIs 
like AZT have been recognized as leading to mitochondrial toxicity and are associated 
with cardiac, hepatic, hematologic, and myopathic morbidity (Lewis and Dalakas 1995).  
Numerous mechanisms have been proposed to explain the deleterious impact of 
NRTIs, including mitochondrial depletion, impaired mitochondrial replication via 
inhibition of the mitochondrial DNA polymerase gamma (POLγ), and subsequent 
increase in ROS (Lewis et al., 2003). POLγ-independent mechanisms of impairing 
mitochondrial function have also been implicated, including decreased mitochondrial 
DNA transcription protein glycosylation, and altered expression of lipid metabolism 
genes (Mallon et al., 2005). Mitochondrial dysfunction is a feature of a number of 
neurodegenerative diseases, including AD, Parkinson’s disease, amyotrophic lateral 
sclerosis, and Huntington’s disease (Knott et al., 2008; Lin and Beal, 2006). Evidence of 
oxidative stress in the CNS has also been demonstrated in patients with HAND (Turchan 
et al., 2003). Proton magnetic resonance spectroscopy illustrates mitochondrial 
dysfunction in patients taking an NRTI as a component of HAART therapy. N-
acetylaspartate levels, a marker of neuronal mitochondrial integrity, are lower in frontal 
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white matter in HIV+ patients taking the NRTIs didanosine or stavudine as compared to 
those who are HIV- or HIV+ on alternative antiretroviral therapy (Schweinsburg et al. 
2005). Additional evidence that NRTI exposure might cause neuronal injury by inducing 
mitochondrial toxicity comes from an investigation of synaptosomes and brain 
mitochondria treated with the NRTI, 2′, 3′-dideoxycytidine (ddC). This treatment led to 
cytochrome c release, decreased expression of the antiapoptotic molecule Bcl-2, and 
increased protein levels of the proapoptotic molecules caspase-3 and Bax, highlighting 
direct pathways between NRTI therapy and neuronal cell death and dysfunction (Opii et 
al., 2007) 
            Another class of drugs primarily involved in HAART treatment includes protease 
inhibitors like indinavir that have been associated with several toxicities. The deleterious 
effects of HIV protease inhibitors have been associated with ROS overproduction and 
also endoplasmic reticulum stress, but the relation between these two events is not 
known. In human aortic endothelial cells, protease inhibitors alone and as part of 
HAART regimens increase ROS production (Jiang et al., 2007). Nelfinavir induces 
oxidative stress and can also lead to adipocyte necrosis (Vincent et al., 2004) and 
premature senescence in human fibroblasts (Caron et al., 2007). In addition, production 
of nitric oxide, a mediator of protein nitrosylation, and other ROS that alter cellular 
redox-dependent reactions interferes with protein disulphide bonding and results in 
misfolding of proteins that accumulate in endoplasmic reticulum lumen. Treatment of 
peripheral blood mononuclear cells from healthy donors with a higher concentration (10 
µM) of an HIV protease inhibitor, saquinavir or indinavir, has induced both a loss in 
mitochondrial membrane potential (ΔΨm) and cell death (Estaquier et al., 2002). 
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Although the exact mechanism still eludes researchers, it is being established that 
protease inhibitors may have the potential for both beneficial and detrimental effects on 
human cells independent of their antiretroviral effects. 
2.8. ROLE OF N-ACETYLCYSTEINE AMIDE (NACA)  
            Glutathione (GSH) and other sulfhydryl-containing compounds are found to be 
decreased in HIV- infected patients’ blood, liver, and cerebro spinal fluid samples. 
Although life expectancy is very poor for these patients, if given GSH, life expectency 
significantly increases. The roles of GSH in the brain are to protect neurons against ROS 
and its stable byproducts, such as hydroxynonenal (Pocernich et al., 2005). GSH is also 
responsible for maintaining redox balance in the brain endothelial cells, thereby 
protecting them from oxidative stress (Toborek et al., 2005), as well as playing a crucial 
role in maintaining the BBB’s normal functions (Agarwal et al., 1999). As a result, the 
compounds that increase intracellular GSH such as N-acetylcysteine (NAC), GSH ethyl 
ester, and GSH, are becoming increasingly popular for treating oxidative stress-related 
disorders. GSH is the principal intracellular thiol responsible for scavenging ROS and 
maintaining the oxidative balance in tissues. Cysteine (Cys) and glutathione delivery 
compounds have been used to protect normal cells from redox imbalance. Therefore, 
thiol-containing compounds gained special attention due to their profound role in 
maintaining tissue redox balance. One of the most widely used thiol antioxidants has 
been NAC (Holdiness et al., 1991).  NAC, the drug of choice in acetaminophen (Tylenol) 
intoxication, indirectly replenished GSH through deacetylation to cysteine, preventing 
oxidative damage through scavenging of ROS (Cotgreave et al., 1997). It has been shown 
that it protects cells from radiation-induced damage (Neal et al., 2003).  
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            NAC was suggested as a therapeutic in HIV-1 infected patients, after the 
discovery of its effect on the inhibition of virus replication in lymphocytes (Staal et al., 
1990). HIV-1 infected patients showed a decrease in GSH and Cys levels; therefore, it 
seemed to be a logical solution to replenish GSH and Cys by NAC (Droge et al., 1992). 
Oral NAC increased the intracellular GSH levels, decreased the mortality rate of patients, 
and prevented the loss of CD4+ T cells. Recently, NAC analogs have been introduced as 
an additional regimen for the treatment of HIV infection (Oiry et al., 2004). However, 
NAC has numerous side effects, including being pro-oxidant, suppressing respiratory 
burst, and causing a toxic ammonia accumulation in case of liver problems (Cotgreave et 
al., 1997). Moreover, NAC’s failure to provide significant antioxidant effects in vivo, 
may be due to its low solubility and tissue distribution (Atlas et al., 1999). A new strategy 
has recently been introduced for improving the pharmacokinetic properties of these 
agents. This was achieved by neutralizing the carboxylic group of NAC, which made the 
drug more lipophilic and cell-permeating (Figure 2.3B). This compound was shown to 
cross the BBB,  scavenge free radicals, chelate copper, and attenuate myelin 
oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune 
encephalomyelitis in a multiple sclerosis mouse model (Offen et al., 2004). Further 
evidence of the efficient membrane permeation of NACA was demonstrated in a recent 
study which assessed NACA for its antioxidant and protective effects in a model using 
human red blood cells (Grinberg et al., 2005).  NACA has been used as a potential 
neuroprotective drug in an animal model of Parkinson’s disease, where it reduces 
neurodegeneration and progression of the disease. NACA passes through the BBB and 
protects the dopaminergic neurons against ROS in in vivo and in vitro models (Bahat et 
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al., 2005). NACA and two other newly synthesized thiols (N-acetyl-gly-cys-amide and 
N-acetyl-Cys-Gly-Pro-Cys-amide) eliminate β amyloid-induced oxidative stress and 
neurotoxicity in vitro (Bartov et al., 2006). It has been suggested that NACA and the 
other aforementioned thiols cross the BBB and scavenge the free radicals directly or 
indirectly by providing Cys and GSH. 
 
(A)                                                                           (B) 

















             N-Acetylcysteine (NAC)   N-Acetylcysteine amide (NACA) 
 
Figure. 2.3. Structures of (A) NAC and (B) NACA. The carboxyl group has been 
replaced by amide in NACA. 
 
 
Recent studies have also investigated the ability of NACA to protect in vitro and 
in vivo from HIV proteins, diesel exhaust particles that induced oxidative stress, and 
toxicity (Banerjee et al., 2010; 2009). Studies from our lab have also reported that NACA 






                                        3.  EXPERIMENTAL DESIGN 
3.1. MATERIALS AND METHODS   
3.1.1. Materials.  N-(1-pyrenyl)-maleimide (NPM) was purchased from Sigma 
(St. Louis, MO). N-acetylcysteine amide was provided by Dr. Glenn Goldstein (David 
Pharmaceuticals, NewYork, NY, USA). High-performance liquid chromatography 
(HPLC) grade solvents were purchased from Fisher Scientific (Fair Lawn, NJ). AZT and 
IDV were a gift from the National Institutes of Health AIDS Research and Reference 
Reagent Program. JC-1 dye (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylben- zimidazolyl 
carbocyanine iodide) and Fura-2AM were purchased from Invitrogen (San Diego, CA). 
Calcein AM was purchased from Biotium, Inc, CA. All other chemicals were purchased 
from Sigma (St. Louis, MO), unless stated otherwise. 
            3.1.2. Culture of Human Brain Microvascular Endothelial Cells 
(hCMEC/D3).  As an in vitro BBB model, immortalized human brain endothelial cells, 
hCMEC/D3 (a gift from Dr. Pierre Couraud), were plated on 25 cm2 tissue culture flasks 
and maintained in EBM-2 medium in humidified 5% CO2/95% air at 37 °C. The culture 
medium was changed twice a week and endothelial cells at passages 28–34 were used in 
this study. A serum-free and growth-factor-free medium was used in the experiments. All 
assays were performed in triplicate and each experiment was repeated three times. The 
EBM-2 medium (Lonza, Walkersville, MD), was supplemented with VEGF, IGF-1, EGF, 
basic FGF, hydrocortisone, ascorbate, gentamycin and 2.5% fetal bovine serum (FBS), as 
recommended by the manufacturer.  
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3.1.3. Cytotoxicity Assay.   hCMEC/D3 cells were seeded in a 96-well plate, at 
densities of  approximately 8x103 cells per well, and were allowed to attach for 24 hr. 
The media was then discarded, and the cells were treated with AZT + IDV combination 
for 24 hr and 72 hr in a serum-free media. For NACA cytotoxicity studies, the cells were 
incubated with various concentrations of NACA for 24 h.  Protective effects of NACA 
were studied by first preincubating cells with NACA for 1 hr and were treated with 
AZT+ IDV for the required time period.  After the treatment, the cells were washed three 
times with phosphate buffered saline (PBS), and 100 μl of 0.4 µM Calcein AM (Biotium 
Inc.) in PBS was added to each well for 30 min at 37 °C. The fluorescence was measured 
with an excitation wavelength at 485 nm and an emission wavelength of 530 nm, using a 
microplate reader (Fluostar, BMG Labtechnologies, Durham, NC, USA). 
            3.1.4. Morphological Assessment of hCMEC/D3 cells.  Treated hCMEC/D3 
cells were assessed for their changes in cellular morphology. An Olympus inverted 
microscope (model CKX1SF) with 20X objective was utilized to observe the changes in 
their morphology. 
            3.1.5. Reactive Oxygen Species (ROS) Measurement.  Intracellular ROS 
generation was measured using a well characterized probe, 2′,7′-dichlorofluorescein 
diacetate (DCFH2-DA) (Wang et al., 1999). DCFH2-DA is hydrolyzed by esterases to 
dichloro -fluorescein (DCFH2), which is trapped within the cell. This nonfluorescent 
molecule is then oxidized to fluorescent dichlorofluorescein (DCF) by the action of 
cellular oxidants. The cells were exposed to the drugs for 48 hr. In order to assess the 
effect of NACA on ROS levels in 100 µM AZT+IDV treated groups, cells were exposed 
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to 2 mM of NACA for 1 hr before the treatment. A DCFH2-DA stock solution (in 
DMSO) of 1mg/ml was diluted in serum-free media to yield a 100 μM working solution. 
Cells were washed twice with PBS and then incubated with a DCFH2-DA working 
solution for half an hour in a dark environment (37 °C incubator). The cells were washed 
with PBS and then fluorescence was measured using a microplate reader.     
            3.1.6. Determination of Glutathione (GSH) Levels.  The level of GSH in the 
cells was determined by RP-HPLC, according to the method developed in our laboratory 
(Winters et al., 1995). The HPLC system (Thermo Electron Corporation) consisted of a 
Finnigan Spectra System vacuum membrane degasser (model SCM1000), a gradient 
pump (model P2000), autosampler (model AS3000), and a fluorescence detector (model 
FL3000) with λex=330 nm and λem=376 nm. The HPLC column used was a Reliasil 
ODS-1 C18 column (5-µm packing material) with 250×4.6 mm i.d (Column Engineering, 
Ontario, CA). The mobile phase (70% acetonitrile and 30% water) was adjusted to a pH 
of 2 with acetic acid and o-phosphoric acid. The NPM derivatives of GSH were eluted 
from the column isocratically at a flow rate of 1 ml/min. The cell pellets obtained were 
homogenized in 1 ml of serine borate buffer (SBB,100 mM Tris buffer containing 10 mM 
borate and 5 mM serine with 1 mM diethylene triaminepentacetic acid; pH=7.4), 
centrifuged, and 250 µl of the supernatant were added to 750 µl of 1 mM NPM. The 
resulting solution was incubated at room temperature for 5 min, and the reaction was 
stopped by adding 10 µl of 2N HCl. The samples were then filtered through a 0.45 µm 
filter and injected into the HPLC system.  
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            3.1.7. Determination of Malondialdehyde (MDA).  The MDA levels were 
determined according to the method described elsewhere (Draper et al., 1993). Briefly, 
550 μl of 5% trichloroacetic acid (TCA) and 100 μl of 500 ppm butylated hydroxytoluene 
(BHT) in methanol were added to 350 μl of the cell homogenates, and boiled for 30 min 
in a water bath. After cooling on ice, the mixtures were centrifuged, and the supernatant 
was collected and mixed 1:1 with saturated thiobarbituric acid (TBA). The mixture was 
again heated in a water bath for 30 min, followed by cooling on ice. 500 μl of the mixture 
were extracted with 1 ml of n-butanol and centrifuged to facilitate the separation of 
phases. The resulting organic layers were first filtered through 0.45 μm filters and then 
injected into the HPLC system (Shimadzu, US), which consisted of a pump (model LC-
6A), a Rheodyne injection valve and a fluorescence detector (model RF 535). The 
column was a 100 × 4.6 mm i.d C18 column (3 µm packing material, Astec, Bellefonte, 
PA). The mobile phase used contained 69.4% sodium phosphate buffer, 30% acetonitrile, 
and 0.6% tetrahydrofuran. The fluorescent product was monitored at λex= 515 nm and 
λem= 550 nm. Malondialdehyde bis (dimethyl acetal), which gives malondialdehyde on 
acid treatment, was used as a standard.  
            3.1.8. Mitochondrial Membrane Potential (ΔΨm).  Mitochondrial membrane 
potential was determined using potentiometric fluorescent dye JC-1 (5,5′,6,6′- 
tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl carbocyanine iodide; Invitrogen, San 
Diego, CA, USA). hCMEC/D3 cells were cultured in glass bottom petri dishes and were 
treated with AZT + IDV (50 µM, 100 µM , 200 µM) for 72 hr. The cells were washed 
twice with PBS and then incubated with JC-1 dye (1 µg/ 1 ml) in media for 30 min. The 
cells were then washed and placed under a fluorescent microscope in phenol red free 
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media. The stained cells were observed with an Olympus IX51 inverted microscope at 
600× total magnification with a UPLFLN 60 X NA 1.25 objective. FITC (EX 482/35 
506DM EM536/40) and TexasRed (EX 562/40 593DM EM 692/40) filters were used 
(Brightline). Images were captured with a Hamamatsu ORCA285 CCD camera. The 
shutters, filters and camera were controlled using SlideBook software (Intelligent 
Imaging Innovations, Denver, CO). 
3.1.9. Measurement of ATP Levels.  Total ATP was quantified using a 
commercially available luciferin–luciferase assay kit (ENLITEN ATP assay kit, 
Promega, WI). A series of dilutions ranging from 0 to 1x10-13 M of the ATP stock 
standard were made using ATP free water supplied in the kit. Using sterile disposable 
tips, 100 µl aliquots of standards were pipetted into a clean 96-well microplate. 
Additionally, 100 µl of cell lysate containing an equal amount of protein was placed into 
the 96 well microplate. Once all of the standards and samples were pipetted, 100 µl 
aliquots of luciferin–luciferase mixture from the ATP assay kit were dispensed into the 
wells. Luminescence was measured after 15 min at 37°C using a luminometer (Fluostar, 
BMG Labtechnologies, Durham, NC, USA). The mean value of the luminescence was 
calculated for each treatment and plotted.   
            3.1.10. Catalase Activity.  The activity of catalase (CAT; EC 1.11.1.6) was 
measured spectrophotometrically at 240 nm, following the exponential disappearance of 
hydrogen peroxide (H2O2; 10 mM), according to the method describe elsewhere (aebi, 
1984). Cell pellets were homogenized in phosphate buffer (50 mM, pH 7.4) containing 1 
mM EDTA and centrifuged at 8500 g for 10 min. An appropriate volume of supernatant 
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was mixed with phosphate buffer (50 mM, pH 7.0) and the reaction was initiated by 
adding a H2O2 solution. The decrease in absorbance at 240 nm was measured for 2 min. 
The catalase activity was calculated using ΔA240/min from the initial linear portion of 
the curve and expressed as units/mg protein. One unit is defined as the amount of enzyme 
that decomposes one micromole of H2O2 per minute under specified conditions of 
temperature and pH (25 °C; pH 7.0). 
            3.1.11. Western Blot Analysis.  Cell homogenates were prepared in a lysis buffer 
(0.5% triton-x-100,  50 mM NaCl, 10 mM Tris, 1 mM EDTA, 1 mM EGTA, 2 mM 
sodium vanadate, 0.2 mM PMSF, 1 mM HEPES, 1 μg/ml leupeptin, and 1 μg/ml  
aprotinin). The cytosolic extracts were cleared by centrifugation at 12,000 xg for 15 min  
at 4°C, and the protein concentration was estimated using a Bio-Rad 250 protein assay kit 
(Bio-Rad, Hercules, CA). Protein samples (40 μg) were resolved by electrophoresis on a 
12% sodium dodecyl sulfate (SDS) polyacrylamide gel (120v, 1.5 hr) in a running gel 
buffer containing 25 mM Tris, pH 8.3, 162 mM glycine, and 0.1% SDS. The samples 
were transferred to nylon membrane for 1 hr and 20 min at 350 mA. The membranes 
were incubated overnight in a mixture of T-TBS with 0.1% Tween in 2% milk and the 
respective antibodies caspase-3 (Santa Cruz biotechnology, Santa Cruz, CA), cytochrome 
c , GAPDH (Cell Signaling Technology, Inc, Danvers, MA) and manganese superoxide 
dismutase (MnSOD; Cayman Chemicals, Ann Arbor, MI) in 1:1000 dilution. 
Subsequently, the membrane was incubated in the respective secondary antibody 
(1:10,000) for 1 hr at room temperature. Final visualization was carried out with the 
enhanced chemiluminescence kit (Bio-Rad, Hercules, CA). The protein bands were 
quantified by densitometry (Haorah et al., 2005). 
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            3.1.12. Apoptosis Measurement.  Apoptosis was quantified using the ethidium 
bromide and Acridine Orange assay (Duke and cohen, 1999). Briefly, control and treated 
cells (106) were transferred to microcentrifuge tubes and pelleted for 10 min at 1,000 xg. 
After centrifugation, the cell-rich pellets were resuspended in a mixture containing 2 µl 
of ethidium bromide (100 µg/ml) and 2 µl of Acridine Orange (100 µg/ml). The stained 
cells were observed with an Olympus IX51 inverted microscope at 600× total 
magnification with a UPLFLN 60 X NA 1.25 objective. FITC (EX 482/35 506DM 
EM536/40) and TexasRed (EX 562/40 593DM EM 692/40) filters were used 
(Brightline). Images were captured with a Hamamatsu ORCA285 CCD camera. The 
shutters, filters and camera were controlled using SlideBook software (Intelligent 
Imaging Innovations, Denver, CO). Live, apoptotic, and necrotic cells were differentiated 
from each other using fluorescence microscopy on the basis of definitive nuclear and 
cytosolic fluorescence and distinct morphological changes, including membrane 
blebbing, nuclear and cytosolic condensation, and nuclear fragmentation.  
             3.1.13. Measurement of Intracellular Calcium Concentration ([Ca2+]in).             
hCMEC/D3 cells were briefly plated on glass-bottom dishes and allowed to attach for 24 
hr. The cells were exposed to different concentrations of AZT + IDV combination for 72 
hr. The cells were washed with PBS and were incubated for 20 min to allow efficient 
loading of membrane permeable Fura-2 AM in a serum-free media. The entire medium 
was then removed and the cells were washed with PBS twice to eliminate 
extracellular Fura-2AM. Following this wash, serum-free medium was added to the cells, 
which were then allowed to reach homeostasis by incubation for the remaining 20 min at 
37 0C. The cells were then placed on the stage of an inverted fluorescence microscope 
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(InCyt Basic IM Fluorescence Imaging System, Intracellular Imaging Inc.). The cells 
were excited at 340 nm and 380 nm while emission was monitored at 510 nm at an 
acquisition rate of 10 Hz. The ratio of fluorescence measured after excitation at the two 
wavelengths (F340/F380) was proportional to the free calcium concentration. In each 
independent experiment, 25 cells were selected to measure the [Ca2+]in and averaged 
(Huang et al., 2010). 
            3.1.14. Trans-Endothelial Electric Resistance (TEER) Measurement.  
Transendothelial electric resistance (TEER) measurement by an EVOM voltohmmeter 
(World Precision Instrument, Sarasota, FL, USA) assessed the tightness of the 
hCMEC/D3 monolayer. hCMEC/D3 cells were seeded onto collagen-coated inserts with 
a pore size of 0.4 μm at densities of 15×103/well, and allowed to culture until a 
monolayer formed (4–7 days). The cell monolayer was then treated with AZT + IDV or a 
serum-free media for 72 hr. After this, the media was replaced with 150 μl of fresh 
medium. The insert containing the cell monolayer was then transferred in to a fresh plate 
containing 500 μl of serum-free medium. The TEER reading was recorded immediately. 
TEER values were calculated as: Resistance×0.33 Ωcm2 (insert surface area) and were 
expressed as a percentage of control. Thus, resistance is inversely proportional to the 
effective membrane (Zhang et al., 2009).  
            3.1.15. Dextran Permeability Study.  hCMEC/D3 cells were seeded onto 
collagen-coated inserts with a pore size of 0.4 μm at densities of 15 × 103/well, and 
allowed to culture until a monolayer formed. The cell monolayer was then treated with 
AZT or serum-free media for 72 hr. After this, the medium in the insert was replaced 
31 
 
with 150 μl of FITC labeled dextran, and was transferred to a fresh plate well, containing 
500 μl of serum-free medium. The plates were incubated for 30 min at room temperature, 
and 100 μl of the plate’s well solution were removed and transferred to a 96-well plate. 
Fluorescence was read with a 485 nm excitation and 530 nm emission, using a microplate 
reader (Fluostar, BMG Labtechnologies, Durham, NC, USA) (Zhang et al., 2009). 
             3.1.16. Determination of Protein.  Protein levels of the cell samples were 
measured by the Bradford method (Bradford, 1976). Concentrated Coomassie Blue (Bio-
Rad, Hercules, CA) was diluted 1:5 (v/v) with distilled water. 20 μl of the diluted cell 
homogenate were then added to 1.5 ml of this diluted dye, and absorbance was measured 
at 595 nm using a UV spectrophotometer (Shimadzu Scientific Instruments, Columbia, 
MD). Bovine serum albumin (BSA) was used as the protein standard. 
            3.1.17. Statistical Analysis.  Group comparisons were performed using the one-
way analysis of variance (ANOVA) test and the TUKEYS post hoc test. Statistical 
analyses were made using GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA). 








                                                 4. IN VITRO RESULTS 
4.1. VIABILITY AND OXIDATIVE STRESS STUDIES 
4.1.1. Antiretroviral Drugs Decrease Viability.  To determine whether the 
HAART drug combination affects the viability of endothelial cells, we treated 
hCMEC/D3 cells with AZT + IDV. Effects of AZT + IDV on cell viability of 
hCMEC/D3 were determined by using the calcein AM assay. Cells were treated with 
drug combinations ranging from 5 µM to 200 µM each, used in previously reported 
studies with immortalized endothelial cells (Collier et al., 2003). Treatment with drugs 
for 24 hr did not show a significant trend by ANOVA, except for the 50 µM, 100 µM, 
and 200 µM treated groups (p<0.05).  However, analysis of individual differences with 
Tukey’s post test showed that only the highest concentration (200µM) was different from 
that of the 50µM and 100 µM treated groups (p<0.05), and produced a moderate decrease 
in cell viability (~ 21% decrease) (Figure 4.1). Treatment with AZT + IDV induced a 
more prominent decrease in viability after 72 hr (Figure 4.2), in a dose-dependent 
manner. 50 µM, 100 µM, and 200 µM concentrations of AZT + IDV caused an increase 
in cell death (approximately 21%, 43%, and 65%, respectively, at p<0.05), and, hence, 
these concentrations of AZT + IDV were used for further studies. 
           The cytotoxic effect of AZT+ IDV treatment assessed using light microscopy 
shows the deleterious effects on viability. Figure 4.3 shows the effect of AZT+IDV on 
morphology of hCMEC/d3 cells. Control cells appear to be well-differentiated whereas 
treated group with AZT+IDV shows round and floating cells indicating cells undergoing 
death. Cells treated with 100 µM of AZT or IDV alone showed that AZT was more toxic 
than IDV in these cells (p<0.05). IDV and AZT alone treated cells showed a decrease in 
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viability of 23% and 34%, respectively, whereas cells treated with an AZT + IDV 
combination showed only a 43% decrease in viability (Figure 4.4). 
            4.1.2. Effect of HAART Drugs on ROS Production.  To examine the role of 
oxidative stress in endothelial cell death, we measured the levels of ROS in endothelial 
cells treated with drugs using the DCFH2-DA fluorescent assay.  ROS are a highly 
transient species and in order to measure them, an intermediate time point of 48 hr was 
selected.  Endothelial cells were incubated with AZT + IDV for 48 hr followed by 
washing to remove the drugs. Re-incubation of hCMEC/D3 cells in the presence of the 
dye DCF for 0.5 hr resulted in an increase in fluorescence compared to control. 
Treatment with AZT + IDV induced a 1.5 to 2 fold increase in ROS production after the 
48-hr treatment (Figure 4.5). Although the ROS levels were different than those of the 
control (p<0.05), no significant difference was observed between those of treated groups.  
            4.1.3. Effect of HAART Drugs on GSH levels.  Oxidative stress or a high level 
of ROS generation leads to the decline in cellular antioxidants like GSH. The levels of 
GSH were measured after treatment with AZT+IDV to further assess the role of oxidative 
stress in cytotoxicity. The levels of glutathione in all treated groups were significantly 
lower than that of the control (Figure 4.6).  In the AZT + IDV treated groups, dose- 
dependent decreases in the GSH levels were observed.  Cells treated with 200 µM 
AZT+IDV had a 65% decrease in GSH  levels, as compared to controls, whereas those 
treated with 100 µM and 50 µM doses experienced decreases of 50 % and 40% with 
respect to that of the control (p<0.05).       
34 
 
4.1.4. HAART Effects on Lipid Peroxidation Levels.  An increase in ROS and 
a decrease in GSH led to high levels of reactions between free radicals and membrane 
lipids, causing lipid peroxidation in the cells. This was estimated by measuring the levels 
of malondialdehyde (MDA), a stable by-product of lipid peroxidation. MDA levels were 
significantly increased in all treated groups, as compared to control. MDA levels in the 
group treated with 50 µM (Figure 4.7) were arithmetically higher, but this did not reach 
statistical significance. A 1.5- to 3-fold increases in MDA levels were observed in the 
cells treated with 100 µM and 200 µM doses of AZT+IDV, as compared to the controls 
(p <0.05). 
4.1.5. Antioxidant Enzyme Activity. Catalase is a common enzyme found in 
nearly all living organisms that are exposed to oxygen, where it functions to catalyze the 
decomposition of hydrogen peroxide to water and oxygen. Activity of catalase in AZT+ 
IDV treated hCMEC/D3 cells is shown in figure 4.8. Catalase activity decreased 
significantly in cells treated with AZT+IDV treated groups (p<0.05). A dose dependent 
decrease in catalase activity was observed indicating that AZT+IDV treatment modified 
the ability of the cells to cleave hydrogen peroxide and protect cells. 
4.2. HAART DRUGS DISRUPT MITOCHONDRIAL FUNCTION 
            4.2.1. Dissipation of Mitochondrial Membrane Potential (ΔΨm). One 
important intracellular target of drugs is mitochondria, which is also a source of ROS 
inside cells. Any disruption in mitochondrial permeability and function can be assessed 
by measuring the changes in mitochondrial membrane potential (ΔΨm). The decrease in 
ΔΨm was demonstrated by using membrane permeable potentiometric dye, JC-1.  Cells 
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with mitochondrial dysfunction showed primarily green fluorescence, whereas healthy 
cells were differentiated with red and green fluorescence. As shown in Figure 4.9, control 
cells stained both red and green, whereas a dose-dependent decrease in red fluorescence 
was seen in treated groups. Although the 200 µM treated group showed specks of red 
fluorescence, these images did not merge into the cytoplasmic area of cells (green 
fluorescence), as seen in previous groups, and appeared to be floating dye aggregates.  
Decreases in the red fluorescence across treated groups indicated that AZT + IDV 
treatment dissipated ΔΨm in the BBB cells. These results support our hypothesis that 
AZT + IDV treatment depolarizes the mitochondria membrane potential, disrupting the 
mitochondrial function, and resulting in cell death.  
            4.2.2. Changes in ATP levels.  ATP levels were measured as another test for 
mitochondrial function. Treatment with AZT + IDV after 72 hr resulted in a dose-
dependent decrease in ATP levels (Figure 4.10).  Compared to control, the ATP levels 
decreased 20-50 % in treated groups (p<0.05). These results also add to the evidence that 
HAART drugs affect mitochondrial function.  
            4.2.3. Effect of AZT+IDV on MnSOD Protein Expression.  hCMEC/D3 cells 
were maintained in supplemented EGM-2 (see Methods). Cells were incubated with 50 
µM, 100 µM, and 200 µM of AZT + IDV for 72 hr. MnSOD protein expression was 
monitored by western blot analysis. The levels of protein expression of MnSOD appeared 
to be slightly elevated in the 50 µM treated group, whereas no change was detected in the 
100 µM sample. There was, however there was a significant decrease in the expression of 
MnSOD protein in the 200 µM treated group (Figure 4.11). 
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 4.3. EFFECT OF HAART DRUGS ON APOPTOTIC CELL DEATH  
            4.3.1. Effect of HAART on Cytochrome c and Procaspase-3 Expression. The 
disruption of mitochondrial membrane function is known to result in the release of the 
mitochondrial enzyme cytochrome c into the cytosol. The levels of cytochrome c release 
were measured to determine if changes in mitochondrial membrane potential correlate 
with the initiation of apoptosis (Skulachev, 1998). Figure 4.12 shows levels of 
cytochrome c released from mitochondria into the cytoplasm. There was an increase 
(~1.5 -2.0 fold) in cytochrome c released in 50 µM and 100 µM (p<0.05).  Cytochrome c 
levels in 200 µM treated group were arithmetically higher, but were not significant when 
compared to that of the control. As additional evidence of apoptosis occurring in 
endothelial cells treated with AZT + IDV, we measured the levels of procaspase-3 
protein, as shown in Figure 4.13. Although there was an increase in the expression of 
procaspase-3 in all treatments, there was an even higher increase in the 50 µM - treated 
cells, as compared to other treated groups.  
            4.3.2. Apoptosis Detection Using Acridine Orange and Ethidium Bromide.  
To corroborate that apoptosis had been induced by AZT+IDV, hCMEC/D3 cells were 
analyzed in the presence of acridine orange and ethidium bromide staining (AO/EB 
staining). Acridine orange is a vital dye that will stain both live and dead cells, whereas 
ethidium bromide will stain only those cells that have lost their membrane integrity 
(Kasibhatla et al., 2006). As a control, cells were cultured in a complete media and 
stained with AO/EB (Figure 4.14A). Cells stained green represented viable cells, whereas 
yellow staining represented early apoptotic cells, and reddish or orange staining indicated 
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late apoptotic cells. As shown in Figure 4.14B, 50 µM treated hCMEC/D3 cells showed 
changes in cellular morphology, including chromatin condensation, membrane blebbing, 
and fragmented nuclei.  Figs. 4.14C and 4.14D showed similar features for  50 µM 
treated cells (Figure 4.14B), but had extra features of late stage apoptotic bodies when 
hCMEC/D3 cells were treated with 100 µM and 200 µM of the AZT + IDV treated 
group.  
 4.4. INTRACELLULAR CALCIUM [CA2+]in MEDIATES APOPTOSIS 
              It is now known that intrinsic pathways in apoptosis involve the exchange of  
Ca2+ signals between the ER and the mitochondria that coordinate the precommitment 
phase of apoptosis (Pinto et al., 2008). It has also been shown that oxidative stress 
increases the intracellular calcium concentration leading to activation of endonucleases, 
which degrade DNA and, ultimately, contribute to cell death (Annuziato et al., 2003)  In 
order to explore the role of calcium in apoptosis by AZT + IDV, we assessed the levels of 
[Ca2+]in  using fluorescent microscopy. We detected a 1.5-2.5 fold increase (p<0.05) in 
calcium levels in the 100 µM and 200 µM treated groups, when compared to levels in the 
control (Figure 4.15). Although the 50 µM treated group showed an increase in 
[Ca2+]in levels, these were not statistically different than those of the control, but 100 µM 
and 200 µM treated groups were different from 50 µM treated group (p<0.05). These 
results imply that [Ca2+]in  mediates the mitochondrial permeability transition, thereby 




4.5. EFFECT OF HAART DRUGS ON THE BBB INTEGRITY 
            Regulation of the flow of substances through intercellular spaces depends on the 
integrity of the BBB.  Permeability studies, such as dextran cell permeability assay and 
TEER assays were used in this study to assess the integrity of a monolayer of endothelial 
cells as they simulate the integrity of the BBB (Gandhi et al., 2010). The resistance 
measured across the monolayer of cells showed a decrease in resistance of approximately 
10-30% across the treated groups (Figure 4.16A). To further support these findings, we 
also measured the amount of FITC labeled dextran that leaked across the monolayer 
using fluorometry after treatment. In agreement with the data for TEER, there was a 10-
60% increase in the permeability of the layer, as seen by the increase in fluorescence 
across the treated groups. In both of these studies, the 100 µM and 200 µM treated groups 
were different from the control (p<0.05). Although the 50 µM treated group was not 
significant when compared to control, they were arithmetically higher than control. 
Tukey post hoc analysis showed that the 100 µM and 200 µM treated groups was 
different from the 50 µM treated group (p<0.05).This indicated that intercellular 
junctions between the endothelial cells were compromised with HAART treatment 
(Figure 4.16B).  
4.6. EFFECT OF NACA ON AZT+IDV INDUCED TOXICITY 
             4.6.1. Cytotoxicity Studies.  Figure 4.17 displays the results of cytotoxicity 
studies of NACA in hCMEC/D3 cells. Cells were incubated with 0.25, 0.5, 0.75, 1, 2, 5, 
10 mM NACA for 24 h, after which calcein AM was added and fluorescence levels were 
measured. Reagent controls and cell controls were included. These results indicated that 
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except the 10 mM NACA treated group all the other groups had cell viability comparable 
to that of the control. The highest concentration of 10 mM NACA appeared to be mild 
cytotoxic to cells, so a minimal dose of 2 mM NACA, the dose without any cytotoxic 
effects was selected for our studies.  
            The protective effect of NACA in AZT+IDV induced cell death in hCMEC/D3 
cells is shown in Figure 4.18.  Although the cells appeared to be rescued from the 
cytotoxic effect of AZT+IDV drugs, the increase in cell viability appear to be arithmetic, 
rather than significant, when compared to the treated group. The viability in the 
AZT+IDV treated group decreased to approximately 65%, when compared to control. 
Pretreatment with NACA could only raise the viability to 77% when compared to control.  
           4.6.2. Reactive Oxygen Species (ROS) Levels.  Our studies with AZT+IDV 
showed a dose dependent increase in ROS levels in endothelial cells. In order to test the 
effect of  NACA on ROS production in AZT+IDV treated  groups, cells were 
preincubated with 2 mM NACA for 1 hr. Figure 4.19 shows the  scavenging effect of 
NACA on  free radicals in treated cells. NACA pretreated hCMEC/D3 cells had 
significantly lower levels of ROS when compared to that of the treated group (p<0.05) 
and it appeared to be almost equal to that of the control. These results suggest that the 
protective effect of NACA may partly be from the ability to scavenge free radicals in 
oxidative stress. 
            4.6.3. NACA Effect on Glutathione (GSH) Levels.  Depletion of cellular 
antioxidants like GSH is commonly observed in oxidatively challenged conditions.  Thiol 
antioxidants are known to replenish cells with GSH levels in these situations, so we 
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tested the ability of NACA to increase GSH levels in AZT+IDV treated. Figure 4.20 
shows the effect of NACA on GSH levels in drug treated groups. GSH levels in 
endothelial cells in the NACA pretreated group had significantly high levels of GSH 
(approximately ~70% of the control) when compared to that of the AZT+IDV treated 
groups (p<0.05). These results suggest that NACA can prevent oxidative stress in cells by 
being uses as substitute to GSH for scavenging free radicals or indirectly by increasing 






















                       
           
Figure 4.1.  Effect of   AZT + IDV treatment for 24 hr on viability. Effect of   AZT + 
IDV treatment for 24 hr (5 µM-200 µM) on hCMEC/D3 cell viability as indicated by 
uptake of calcein. Results as mean percent of controls (Mean±SEM; n=5). * Statistical 
differences (p<0.05) as compared to untreated control. # Statistical difference (p<0.05) 
















                    
Figure 4.2.  Effect of   AZT + IDV treatment for 72 hr on viability. Effect of   AZT + 
IDV treatment for 72 hr (5 µM-200 µM) on  hCMEC/D3 cell viability, as indicated by 
uptake of calcein. Results as mean percent of controls (Mean±SEM; n=5). * Statistical 













   (A) Control                                                          (B)   AZT+IDV (200 µM) 
Figure 4.3. Morphological assessment of AZT +IDV treatment. hCMEC/D3 cells were 
treated with  or without AZT+IDV (200 µM)  for 72 hr. The morphology was assessed 












                      
Figure 4.4.  Effect of AZT or IDV alone on viability. Effect of AZT or IDV alone and in 
combination treatment (100 µM) for 72hr on hCMEC/D3 cell viability as indicated by 
uptake of calcein. Results as mean percent of controls (Mean±SEM; n=5). * Statistical 
differences (p<0.05) as compared to untreated control. *** Statistical difference (p<0.05) 












              
Figure 4.5. Reactive oxygen species (ROS) production. Reactive oxygen species (ROS) 
production induced in hCMEC/D3 cells treated with 50 µM, 100 µM and 200 µM, AZT 
+IDV for 48 hr. Cellular ROS levels were assessed using DCFH2-DA. Results expressed 












                      
Figure 4.6. Glutathione (GSH). AZT + IDV (50 µM, 100 µM, and 200 µM) exposure led 
to intracellular glutathione (GSH) decrease in a dose-dependent manner. hCMEC/D3 
cells were treated for 72 hr and GSH levels were measured using HPLC method 
described in Materials and Methods section. Results expressed as mean percent of 











                   
Figure 4.7. Lipid peroxidation levels.  Lipid peroxidation in hCMEC/D3 cells. AZT + 
IDV (50 µM, 100 µM, 200 µM) treatment for 72 hr caused oxidative stress resulting in an 
increase in malondialdehyde (MDA) levels, a lipid peroxidation metabolite. MDA levels 
were measured using HPLC method described in the Materials and Methods section. 
Results expressed as mean percent of controls (Mean±SEM; n=4). ). * Statistical 










                   
Figure 4.8.  Effect of AZT+ IDV on antioxidant enzyme catalase activity. Cells were 
treated for 72 hr with the drug combination and activity was estimated using spectro 
photometric method. Each value is an average of at least triplicate values with standard 










                                          
Figure 4.9.  Analysis of mitochondrial membrane potential.  ΔΨm was analyzed in 
adherent hCMEC/D3 after 72 hr of AZT+IDV treatment, using the potential-dependent 
aggregate-forming lipophilic cation JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-
tetraethylbenzimidazole carbocyanide iodide). Left image represents JC-1 dye 
aggregation in mitochondria with intact membrane potential. Mitochondria exhibit red 
fluorescence if ΔΨm is preserved. Middle image represents JC-1 monomers exhibiting 
green fluorescence in cytoplasm of cells. Mitochondria in treated cells showed a dose-
dependent decrease in red fluorescence due to loss of ΔΨm.  Merged images are 
represented on extreme right. Each experiment was performed in triplicate (n = 3) and 




                                 
Figure 4.10. ATP levels. ATP levels were measured with the bioluminescence assay 
(Promega) in AZT + IDV (50 µM, 100 µM, 200 µM) treated cells for 72 hr.  Exposure to 
drugs showed a dose-dependent decrease in ATP levels. * Statistical differences (p<0.05) 

















                     
                          
 
Figure 4.11. Expression of manganese superoxide dismutase protein. (MnSOD)The 
expression of manganese superoxide dismuatase in  hCMEC/D3 cells treated with AZT + 
IDV for 72 hr Equal amounts of cellular protein were separated on 12% SDS-PAGE gels 
and transferred to nitrocellulose membranes as described in Materials and Methods. 
















                      
 
 
Figure 4.12. The expression of apoptosis-related protein  cytochrome c.  hCMEC/D3 
cells treated with AZT + IDV for 72 hr. Equal amounts of cellular protein were 
fractionated on 12% SDS-PAGE gels and transferred to nitrocellulose membranes as 












                
Figure 4.13. The expression of apoptosis-related protein procaspase-3. hCMEC/D3cells 
treated with AZT + IDV for 72 hr. Equal amounts of cellular protein were separated on 
12% SDS-PAGE gels and transferred to nitrocellulose membranes as described in 











                
                                       
  
Figure 4.14.  Apoptosis detection using acridine orange with ethidium staining. 
hCMEC/D3 cells were treated with AZT + IDV for 72 hr and were stained with AO/EB 
mixture. (A) Control and viable cells appearing only green due to acridine orange 
staining. (B) 50 µM treated hCMEC/D3 cells showing changes in cellular morphology 
for early apoptosis and appearing orange with ethidium staining. Dashed arrow indicates 
cells with chromatin condensation; rounded dotted arrow indicates cells with fragmented 
nuclei; dashed dotted arrow indicates cells with membrane blebbing. (C) 100 µM treated 
group showing morphological similar to 50 µM treated group with some late apoptotic 
features.  Full white arrow indicates the presence of apoptotic bodies. (D) 200 µM treated 
group with cells showing chromatin condensation and late apoptotic features like 
apoptotic bodies. Necrotic cells appearing red with ethidium staining. Each experiment 




Figure 4.15. Effect of AZT + IDV treatment on intracellular calcium levels [Ca2+]in 
  hCMEC/D3 cells were treated with AZT + IDV for 72 hr and calcium levels were 
measured as  described in Material and Methods section. Results expressed as mean 
percent of controls (Mean±SEM; n=3). Each value is average of atleast triplicate values 
with standard error mean bars. * Statistical differences (p<0.05) as compared to untreated 














                     
  
                    
Figure 4.16. Effect of AZT + IDV on TEER and dextran permeability. (A) AZT + IDV 
treatment significantly reduced TEER, and TEER measurement across the hCMEC/D3 
monlayer measured the BBB integrity and tightness. TEER values recorded in ohms 
(Ω)/insert area were corrected to Ω/cm2 from three experiments in triplicate. Results as 
mean percent of control (Mean±SEM; n=3).  (B) Monolayer treatment for 72 hr with 
AZT + IDV increased the permeability of FITC-labeled dextran across the BBB.  
Fluorescence measured was then expressed as mean percent of control (Mean±SEM; 
n=3). * Statistical differences (p<0.05) as compared to untreated control. *** Statistical 





                
 
Figure 4.17. Effect of NACA on hCMEC/D3 cell viability. Cells were treated with 
different concentrations of NACA in serum free media and viability was assessed using 
calcein assay. Each value is an average of at least triplicate values with standard error 



















                         
Figure 4.18. Effect of NACA on AZT+IDV induced cell death.  Cells were pretreated 
with 2 mM NACA for 1 hr and then exposed to AZT+IDV (100 µM) for 72 hr. Viability 
was assessed using calcein AM fluorescent assay. Each value is the average of at least 









                
 
Figure 4.19. Effect of NACA on AZT+IDV induced ROS production.  Cells were 
pretreated with 2 mM NACA for 1 hr and then exposed to AZT+IDV (100 µM) for 72 hr. 
Results are expressed as mean percent controls (Mean± SEM; n=4). * Statistical 
differences (p<0.05) as compared to untreated control. # Statistical differences (p<0.05) 















       
 
 Figure 4.20. Effect of NACA on GSH levels in AZT+IDV treated cells. hCMEC/D3 
cells were pretreated with 2 mM NACA for 1 hr and then exposed to AZT+IDV (100 
µM) for 72 hr. Results are expressed as mean percent controls (Mean± SEM; n=4). * 
Statistical differences (p<0.05) as compared to untreated control. # Statistical difference 
(p<0.05) compared to AZT+IDV treated group. 
 
















                                 5. INVIVO EXPERIMENTS 
5.1 MATERIALS AND METHODS 
             
            5.1.1 Materials. F344 rats (normal and HIV-1 transgenic) were obtained from 
Harlan Laboratories (Indianapolis, IN). N-acetylcysteine amide was provided by Dr. 
Glenn Goldstein (David Pharmaceuticals, NewYork, NY, USA). N-(1-pyrenyl)-
maleimide (NPM) was purchased from Sigma (St. Louis, MO). High-performance liquid 
chromatography (HPLC) grade solvents were purchased from Fisher Scientific (Fair 
Lawn, NJ). Antiretroviral drugs (ART), AZT and IDV were a gift from the National 
Institutes of Health AIDS Research and Reference Reagent Program. All other chemicals 
were purchased from Sigma (St. Louis, MO), unless stated otherwise. 
            5.1.2. Animal Experiments. Male F344 normal and HIV-1 transgenic (Tg) rats 
(200-250 g, 3 months old) were housed in a controlled temperature (20–23 0C) and 
controlled-humidity (~55%), in an animal facility, with a 12 h light and dark cycle. The 
animals had unlimited access to rodent chow and water, and were utilized after 1week of 
acclimatization. All animal procedures were conducted under an animal protocol 
approved by the Institutional Animal Care and Use Committee of the Missouri University 
of Science and Technology. The normal rats were divided into control and NACA 
control. HIV Tg rats were classified as experimental group.  The HIV Tg rats in the 
experimental group further were divided into four major groups (n = 4 each): HIV group, 
HIV+ART, HIV+ NACA and HIV+ ART +NACA. All animals in the control and 
experimental groups were injected intraperitoneally (i.p) with either saline or NACA (500 
mg/kg body weight), 30 min before exposure to ART drugs. The animals in the 
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respective experimental group were injected i.p with ART drugs (AZT+IDV, each 
15mg/kg body weight for 10 days (Jiang et al., 2009). The rats were sacrificed 24 h after 
the last exposure by urethane injection. All rats were weighed at the beginning and at the 
end of the study. Following sacrifice, the brains were harvested and divided into two 
parts, and the first half were placed in a cold stock buffer (25 mM HEPES, 1% dextran in 
minimum essential medium) (Gibco BRL, Grand Island, N.Y.), at pH 7.4 on ice and the 
remaining tissue was stored in an antioxidant buffer [8.6mM sodium phosphate dibasic 
(Na2HPO4), 26.6 mM sodium phosphate monobasic (NaH2PO4), 50 µM 
butylhydroxytoluene (BHT), 10mM aminotriazole, 0.1mM diethyltriaminepentaacetic  
acid (DTPA)] at −80 0C for further analysis. 
            5.1.3 Isolation of Brain Microvessels. Microvascular endothelial cells were 
isolated using an established protocol (Wu et al., 2003). Briefly, brain tissues from rats 
were homogenized in cold stock buffer (25 mM HEPES, 1% dextran in minimum 
essential medium) (Gibco BRL, Grand Island, N.Y.), at pH 7.4 on ice. The homogenates 
were then filtered through a series of nylon mesh membranes, after which they were 
mixed with an equal volume of 40% dextran in stock buffer, and centrifuged at 5,000 × g 
for 15 min at 4°C. The pellet obtained is re-suspended in a stock buffer and filtered 
through a 25-µm pore-size nylon mesh membrane (Bio-Design, Carmel, NY). The micro-
vessels were then washed from the surface of the membrane with the stock buffer, 
collected, and centrifuged at 5,000 × g for 15 min at 4°C, after which they were re-
suspended in an incubation buffer [129 mM NaCl, 2.5 mM KCl, 7.4 mM Na2HPO4, 
1.3 mM KH2PO4, 0.63 mM CaCl2, 0.74 mM MgSO4, 5.3 mM glucose, 0.1 mM ascorbic 
acid (pH 7.4)], with a small aliquot being reserved for verification of an enriched micro-
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vessel preparation by light microscopy. About 97.5% of the cells isolated were capillary 
endothelial cells, 1.6% were fibroblast-like cells, and 0.9% were erythrocytes. There were 
no glias, neurons, synaptosomes, or synaptic complexes, although there were some other 
membrane profiles and myelin fragments. 
            5.1.4. Determination of Glutathione (GSH) Levels. The levels of GSH in the 
BBB microvessels and brain were determined by RP-HPLC, according to the method 
developed in our laboratory (Winters et al., 1995). The HPLC system (Thermo Electron 
Corporation) consisted of a Finnigan Spectra System vacuum membrane degasser (model 
SCM1000), a gradient pump (model P2000), autosampler (model AS3000), and a 
fluorescence detector (model FL3000) with λex=330 nm and λem=376 nm. The HPLC 
column used was a Reliasil ODS-1 C18 column (5-µm packing material) with 250×4.6 
mm i.d (Column Engineering, Ontario, CA). The mobile phase (70% acetonitrile and 
30% water) was adjusted to a pH of 2 with acetic acid and o-phosphoric acid. The NPM 
derivatives of GSH were eluted from the column isocratically at a flow rate of 1 ml/min. 
The microvessel pellets or brain tissues  obtained  were homogenized in 1 ml of serine 
borate buffer (SBB,100 mM Tris buffer containing 10 mM borate and 5 mM serine with 
1 mM diethylene triaminepentacetic acid; Ph=7.4), centrifuged, and 250 µl of the 
supernatants  were added to 750 µl of 1 mM NPM. The resulting solution was incubated 
at room temperature for 5 min, and the reaction was stopped by adding 10 µl of 2N HCl. 




            5.1.5. Determination of Malondialdehyde (MDA). The MDA levels were 
determined according to the method described elsewhere (Draper et al). Briefly, 550 μl of 
5% trichloroacetic acid (TCA) and 100 μl of 500 ppm butylated hydroxytoluene (BHT) in 
methanol was added to 350 μl of the BBB microvessel or brain homogenates, and boiled 
for 30 min in a water bath. After cooling on ice, the mixtures were centrifuged, and the 
supernatant was collected and mixed 1:1 with saturated thiobarbituric acid (TBA). The 
mixture was again heated in a water bath for 30 min, followed by cooling on ice. 500 μl 
of the mixture was extracted with 1 ml of n-butanol and centrifuged to facilitate the 
separation of phases. The resulting organic layers  first filtered through 0.45 μm filters 
and then injected into the HPLC system (Shimadzu, US), which consisted of a pump 
(model LC-6A), a Rheodyne injection valve and a fluorescence detector (model RF 535). 
The column was a 100 × 4.6 mm i.d C18 column (3 µm packing material, Astec, 
Bellefonte, PA). The mobile phase used contained 69.4% sodium phosphate buffer, 30% 
acetonitrile, and 0.6% tetrahydrofuran. The fluorescent product was monitored at λex= 
515 nm and λem= 550 nm. Malondialdehyde bis (dimethyl acetal), which gives 
malondialdehyde on acid treatment, was used as a standard.  
            5.1.6. Measurement of Superoxide Levels.  BBB microvessels were  suspended 
in PBS, pH 7.2, containing 100 μg/ml bovine serum albumin and protease inhibitor 
cocktail (EDTA free complete protease mix; Roche Diagnostics, Indianapolis, IN). 
Reduced streptolysin O (5 units/ml; Sigma Aldrich) was added, and the mixture was 
incubated for 10 min at 37 °C (O’brien et al., 2009). The permeabilized cells were chilled 
to 4 °C, harvested by centrifugation, and washed with phosphate buffer, pH 7.2. To 
measure superoxide production, brain microvessels were resuspended in duplicate tubes, 
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with and without 200 units of SOD, containing 30 mM of 3-(N-morpholino) 
propanesulfonic acid (MOPS (pH 7.2), 100 μM flavin adenine dinucleotide (FAD), and 
100 μM oxidized cytochrome c, incubated at room temperature for 5 min, and 
nicotinamide adenine dinucleotide phosphate (NADPH) added to a final concentration of 
200 μM. The change in optical density at 550 nm was recorded every 5 min for 1 hr. At 
the conclusion of the experiment, cells were lysed in 20 mM HEPES buffer containing 
1% Triton X-100, and the protein was quantitated using the biorad protein assay. 
Superoxide production was expressed as SOD-inhibitable cytochrome c 
reduction/min/mg protein. 
            5.1.7. Measurement of NADPH Oxidase Activity. NADPH oxidase activity was 
measured in brain using the lucigenin assay. Briefly, frozen brain samples were 
homogenized in protease inhibitor-containing buffer at 4°C, and then subjected to 
differential centrifugation to isolate purified cell membranes (obtained after sequential 
centrifugations of 1300 x g to remove nuclei, 13,000 x g to remove mitochondria). 
Membrane samples were then incubated with 5 µM lucigenin and 100 µM NADPH, and 
NADPH oxidase activity was measured immediately using a luminescence plate reader at 
37°C. To eliminate the background level of luminescence, membrane fractions of the 
samples were also incubated in the presence of 1 µM diphenyl iodonium chloride (DPI), 
a broad-spectrum flavin oxidase inhibitor. 
            5.1.8. Measurement of Nitrite Levels in the Brain. Nitrite levels in the BBB 
microvessels were determined using a commercially available kit from Cayman Chemical 
Company (Ann Arbor, MI).  Briefly, this assay measures the nitrite concentration in two-
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steps. The first step involves the conversion of nitrate to nitrite using nitrate reductase, 
and the second step converts the nitrite into a deep purple azo compound using the greiss 
reagent. Photometric determination of the absorption at 540 nm accurately determines the 
NO2- concentration. 
             5.1.9. Determination of Protein. Protein levels of the cell samples were 
measured by the Bradford method. Concentrated Coomassie Blue (Bio-Rad, Hercules, 
CA) was diluted 1:5 (v/v) with distilled water. 20 μl of the diluted cell homogenate was 
added to 1.5 ml of this diluted dye, and absorbance was measured at 595 nm using a UV 
spectrophotometer (Shimadzu Scientific Instruments, Columbia, MD). Bovine serum 
albumin (BSA) was used as the protein standard. 
            5.1.10. Statistical Analysis. Group comparisons were performed using the one-
way analysis of variance (ANOVA) test and the TUKEYS post hoc test. Statistical 
analyses were made using GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA). 
Statistical significance was set at p < 0.05. 
5.2.  IN VIVO RESULTS 
            5.2.1. Changes in Glutathione Levels of Brain Microvessels and Brain. Table 
5.1 shows the effect of viral proteins and ART drugs on GSH levels in blood-brain 
barrier. Compared to the controls, the HIV treated animals had a decrease (~ 3 fold) in 
the GSH levels in their blood brain barrier. A significant and drastic decrease (~ 6 fold) 
in the levels of GSH was observed in HIV transgenic animals treated with ART drugs 
when compared to controls. In this study, animals treated with ART also experienced a ~ 
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1.5 fold decrease in GSH levels, as compared to the HIV group.  Animals pretreated with 
NACA in both the HIV and HIV +ART groups showed an increase in GSH levels.  
             Evaluation of GSH levels in the brains of HIV transgenic animals and ART 
treated group are shown in Table 5.1. Compared to control, the HIV transgenic animals 
had a significantly lower level of GSH. Similarly, the HIV+ART group also had 
decreased levels of GSH in relation to control. There was no significant difference 
observed between the HIV and ART treated HIV group. Treatment with NACA elevated 
the GSH to a level similar to that of control group in both the HIV and ART treated 
group.  These results suggest that viral proteins induce oxidative stress by decreasing the 
levels of GSH and these effects appear to be more potentiated with concomitant use of 
ART drugs. These outcomes also indicate the potent antioxidant ability of NACA to 
reverse these effects and replenish GSH in oxidatively challenged cells.     
            5.2.2. Effect of HIV Proteins and ART on MDA Levels in Brain.  A significant 
increase in the level of MDA was observed in the brain tissue of HIV transgenic animals, 
as compared to those of the control and the NACA-alone treated group. HIV Tg animals 
treated with ART had a higher MDA levels than those of the control, but were similar to 
those of HIV group (Table 5.2). However, animals in the HIV group, pre-treated with 
NACA, had significantly lower MDA level than those of the untreated group, indicating 
that NACA was protecting the animals from oxidative stress-induced damage.  Also 
animals in the HIV+ART group had lower levels of MDA than those of the control 
group, but similar to those of NACA group. 
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           5.2.3. NADPH Oxidase Activity. The NADPH oxidase, a membrane-
bound enzyme complex, normally generates superoxide by electrons by transferring 
electrons from NADPH inside the cell across the membrane and coupling these to 
molecular oxygen to produce the superoxide radical (O2*-).  Figure 5.1 shows that, 
compared to the controls, HIV and HIV+ART treated animals experienced a significant 
increase in the NADPH oxidase activity in the brain. Pretreatment of the HIV+ART 
treated animals with NACA significantly decreased the NADPH oxidase activity, 
indicating that NADPH oxidase activation might be one of the reasons for increased 
oxidative stress in these animals. 
           5.2.4. Effect of ART Drugs on Superoxide levels in BBB.  Several studies have 
shown that NADPH oxidase is the most important source of superoxide anion in 
phagocytic and vascular cells. Increase in NADPH oxidase activity is correlated to 
increase in superoxide levels. Figure 5.2 displays the results of superoxide levels in 
blood-brain barrier. Although superoxide levels were unchanged in HIV Tg group, ART 
treated HIV group showed a significant (~6 fold) increase in superoxide levels (p<0.05). 
Pretreatment with NACA decreased the superoxide levels to remarkably lower levels, 
similar to that of control group (p<0.05). These results indicate NADPH oxidase enzyme 
may be involved in the oxidative stress induced by ART drug in BBB. 
            5.2.5. Nitrite Levels in Brain after AZT+IDV Treatment.  Activation of 
NADPH oxidase enzyme results in an increase in the superoxide levels (O2·–). Superoxide 
radicals react with nitric oxide (NO·), which gives rise to highly pro-oxidant peroxynitrite 
(ONOO–). This compound triggers the formation of nitrotyrosine residues (Ntyr), which 
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provides a tissue marker for reactive nitrogen-related tissue damage. Figure 5.3 displays 
the increase in levels of nitrite in the brain samples of both HIV group as well as the ART 
drug treated HIV group.  The increases in the nitrite levels in both groups were 
significantly different from control and the nitrite levels of brain were higher in ART 
treated group than HIV transgenic animals. There was significant decrease in nitrite 
levels of brain samples of NACA treated HIV+ART group.  These results indicate the 
involvement of a convergent mechanism in BBB dysfunction and also show that NACA 














Table 5.1. GSH levels in BBB and Brain of HIV-Tg rats. (GSH: nmoles/mg of protein). 
Results expressed as mean values (Mean±SEM; n=4). * Statistical differences (p<0.05) 
as compared to untreated control, ** (p<0.05) compared to HIV treated group, # (p<0.05) 
compared to HIV+ART treated group. 
 
Groups                        GSH  
 Brain microvessels Whole brain  
     
Control     5.7±0.6       15.1±1.6  
NACA 3.2±0.5       16.4±5.0  
HIV   1.6±0.1*   10.7±1.1*  
HIV+NACA     2.2±0.1**       19.1±8.6  
HIV+ART   0.9±0.1*   12.0±1.3*  





















Table 5.2.  MDA levels in Brain of HIV-Tg rats. (MDA: nmoles/100mg of protein).  * 
Statistical differences (p<0.05) as compared to untreated control, ** (p<0.05) compared 
to HIV treated group, # (p<0.05) compared to HIV+ART treated group (Mean±SEM; 
n=4). 
Groups        MDA              
 
Control 67.0±3.7  
NACA      55.9±2.6  
HIV  78.1±3.8*  
HIV+NACA    50.2±8.8**  
HIV+ART  73.0±3.1*  
HIV+ART+NACA   55.9±6.2#  












              
 
Fıgure 5.1.  Effect of ART drugs and NACA on activity of NADPH oxidase. NADPH 
oxidase activity was measured in the brain of HIV-Tg animals treated with ART 
(AZT+IDV) drugs for 10 days. Animals in the NACA group pretreated with NACA 30 
mins before ART drug injection. NADPH oxidase activity of the NACA alone and 
HIV+NACA treated group similar to that of the control (data not shown). Data: 
Mean±SEM; n=4. (*) indicates significantly different from the control, (!) significantly 

















           
Fıgure 5.2. Effect of NACA on superoxide levels.  Superoxide radical formation was 
measured in the BBB in the brain of HIV-Tg animals treated with ART drugs 
(AZT+IDV) drugs for 10 days. Animals in the NACA group pretreated with NACA 30 
mins before ART drug injection. Superoxide radical formation of the NACA alone and 
HIV+NACA treated group similar to that of the control. Data: Mean±SEM; n=4. (*) 
indicates significantly different from the control, (!) significantly different from the 








                   
 
Fıgure 5.3. Effect of ART drugs and NACA on nitrite levels. Brain nitrite levels shown 

















                                                       6. DISCUSSION 
6.1. IN VITRO RESULTS   
            The advent of HAART therapy has significantly revolutionized the treatment of 
AIDS by increasing the lifespan of HIV-infected individuals, and creating a decline in 
AIDS-related neurological disorders (Bell, 1998; Nath, 2002). Although HAART 
treatment has reduced the prevalence of opportunistic infections like cytomegalovirus and 
toxoplasmosis, the clinical impact of HAART toxicity on HIV-1-associated 
neurocognitive disorders is still controversial (Krebs et al., 2000).  Most of the clinical 
studies report that cognitive impairment is still a significant clinical problem in HAART-
treated patients (Dore et al., 1999). Although several in vitro studies have shown that 
HIV proteins and methamphetamine can cause dysfunction in the BBB, the effect of 
HAART drugs on the BBB endothelial cells and its role in exacerbating HAND are not 
yet known. In this study, we have used the combination of AZT and IDV, one of the most 
commonly recommended HAART regimens, to elucidate their role in free radical 
generation and mitochondrial dysfunction mediated endothelial cell death. 
            Here, we present evidence that HAART drugs are toxic to BBB endothelial cells 
in a dose-dependent manner (Figure 4.1). We suggest that the high AZT and IDV 
concentrations found to be active in our studies can be considered relevant.  AZT + IDV 
is used for the treatment of HIV-infected AIDS patients at doses of about 500–1500 mg 
daily for a long survival period.  The concentrations used in our experiments are achieved 
at serum levels after oral administration (Collier et al., 2003). Endothelial cells exposed 
to individual drugs showed that AZT was more toxic than IDV. AZT, a nucleoside 
reverse transcriptase inhibitor, has been shown to decrease the levels of mitochondrial 
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DNA in vivo and clinically by inhibiting γ-DNA polymerase (Simpson et al., 1989; Lewis 
et al., 1992). The decrease in mtDNA inhibits the synthesis of adequate proteins for 
oxidative phosphorylation (OXPHOS). A subsequent energy loss and increase in 
production of reactive oxygen species (ROS) has been reported in other studies involving 
HAART treatment (Mondal et al., 2004). Our data concurs with those studies, as a 
significant, concentration-dependent increase in total ROS was also observed in our 
study, indicating an increase in the oxidative stress in response to the treatment (Figure 
4.5).  
            One of the important effects of oxidative stress and free radical generation is 
decreased levels of cellular antioxidants. GSH (γ-glutamyl-cysteinyl-glycine), a thiol 
antioxidant in cells, is mainly responsible for maintaining cellular redox status in 
endothelial cells. GSH scavenges free radicals and hydrogen peroxide, and neutralizes 
toxic metabolites by condensing with them both enzymatically and nonenzymatically 
(Meister, 1995). Long-term AZT treatment has been shown to induce oxidative damage 
and deplete GSH in rats treated acutely and in cell cultures (Szabados et al., 1999). We 
observed a dose-dependent decrease in GSH levels after HAART treatment suggesting 
that AZT + IDV induced ROS production with subsequent decreases in GSH levels 
(Figure 4.6).  AZT + IDV may have caused an increase in levels of hydroperoxides that 
exceeded the metabolic capabilities of the glutathione system to maintain glutathione in 
the reduced form. In fact, mitochondria are highly dependent on glutathione to detoxify 
ROS and prevent oxidative damage (Lewis et al., 1995). 
            A decrease in GSH and an increase in ROS set off a cascade of further oxidative 
damage. An important target of oxidative damage is brain microvessel endothelial cells 
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because they are rich in polyunsaturated fatty acids (PUFAs). ROS attacks double bonds 
in PUFAs, thereby degrading the lipids and generating MDA as by product. MDA is a 
widely used oxidative stress parameter, reacting with deoxyadenosine and 
deoxyguanosine to form mutagenic DNA adducts (Marnett, 1999).  Studies have shown 
that AZT treated mice have higher levels of plasma MDA, as compared to control mice 
(Garcia et al., 2007).Our results also indicated that AZT + IDV treatment increased the 
levels of lipid peroxidation metabolites because of oxidative damage (Fig. 4.7).  
            The predominant enzymatic mechanisms that regulate intracellular H2O2 levels 
are mediated by catalase and glutathione peroxidase. In the current study, catalase 
activity of hCMEC/D3cells after exposure to AZT+IDV was measured by following the 
disappearance of H2O2. As indicated in figure (4.8), a dose dependent decrease in catalase 
activity was seen after 72 hr exposure to AZT+IDV.  The ability of AZT+IDV to reduce 
catalase activity has been shown before in other models, such as the human umbilical 
endothelial cell line, HUVEC. Transduction with the mitochondria-targeted catalase 
(mCAT) was more effective than cytoplasmic catalase in inhibiting the ROS and 8-
isoprostane (8-iso-PGF2alpha) produced after treatment with either AZT or indinavir 
(Jiang et al., 2007). Similarly transgenic animals overexpressing mCAT treated with AZT 
were protected from cardiac dysfunction (Kohler et al., 2009). It is so far poorly 
understood through which mechanisms AZT and IDV affect the function of catalase. 
However it is thought that tyrosyl radical in catalase enzyme is involved in the in the 
catalytic activity of the enzyme (Ivancich et al., 1997; Chouchane et al, 2002). Nitration 
or reaction of free radicals with this tyrosine residue could lead to inactivation of the 
enzyme.  Other studies have reported that phosphorylation of the tyrosine residue on 
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catalase may lead to decreased activity of catalase enzyme (Zhang et al., 2005; Suarez et 
al., 2009). 
           Mitochondria are logical targets for oxidative stress, based on their ability to 
generate free radicals, and may be primarily involved in oxidative stress associated with 
AIDS treatment. Under physiological conditions, reactive oxygen species (ROS) are 
produced mainly by the mitochondria during OXPHOS, as electrons travel through the 
electron transport chain (ETC).  During OXPHOS, electrons leak out of the ETC and 
result in the formation of superoxide instead of water. Superoxide is generated at 
complex I (NADH dehydrognase) and complex III (ubiquinone Q-cytochrome b). Any 
alteration in redox status of these complexes results in an excessive production of 
superoxide radical (Boveris et al., 1973). Mitochondrial hydrogen peroxide is also rapidly 
formed from superoxide by dismutation or by mitochondrial manganese superoxide 
dismutase. Hydroxyl radicals are known to form at sites where superoxide and hydrogen 
peroxide are formed in mitochondria (Taylor et al., 1995). The free radicals generated can 
act on mitochondrial proteins, lipids, and even mtDNA, thereby altering the 
electrochemical gradient across the mitochondria resulting in mitochondrial dysfunction 
(Lin et al., 2006). An electrochemical gradient across mitochondrial inner membrane or 
mitochondrial membrane potential (ΔΨm) is important for mitochondrial electron 
transport and energy metabolism. A decrease in ΔΨm after treatment was detected and 
assessed in our studies by using fluorescent microscopy. In addition to this, we also 
observed a dose-dependent decrease in ATP levels after treatment. Loss of ΔΨm 
interferes with the production of ATP, the cell's main source of energy, because 
mitochondria must have an electrochemical gradient to provide the driving force for ATP 
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production. Decreases in ΔΨm and ATP levels seen in our study are consistent with 
disrupted mitochondrial function. 
           To determine the oxidative stress effect of AZT+IDV, the expression of MnSOD 
expression was evaluated. Results from 50 µM indeed support the fact, as seen by 
increased expression of MnSOD.  In support to our results, various other studies have 
reported that a mild to moderate increase in oxidative stress increased MnSOD 
expression in various cell types (Li et al., 2010; Liu et al., 2010). Higher or 
overwhelming oxidative stress tends to decrease the expression of MnSOD levels as seen 
from results in 200 µM treated groups (Chaudauri et al., 2010).  
            Reactive oxygen and nitrogen species, decreased mitochondrial membrane 
potential, and oxidation of pyridine nucleotides and glutathione all promote 
mitochondrial damage and the onset of a phenomenon known as mitochondrial 
permeability transition (MPT). MPT is a sudden increase in the permeability of the inner 
mitochondrial membrane, loss of ΔΨm, uncoupling of oxidative phosphorylation, 
mitochondrial swelling, and the release of intramitochondrial ions through the 
mitochondrial membrane transition pore (MPTP) (Lemasters et al., 1998). Mitochondrial 
permeability transition (MPT), is recognized as an initiating phenomenon, important for 
both necrosis and apoptosis (Lemasters et al., 1998). Swelling of the mitochondria due to 
increased permeability ruptures the outer membrane of the mitochondria releasing the 
cytochrome c into the cytoplasm. Cytochrome c can, in turn, cause apoptosis of cells by 
activating pro-apoptotic factors (Skulachev, 1998). Endothelial cell apoptosis has been 
demonstrated in an atherosclerotic lesion and has been considered a mechanism for 
atherogensis in HAART-treated patients (Barbaro et al., 2006). AZT treatment has 
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induced apoptosis in placental cells and parathyroid cancer cells (Falchetti et al., 2005). 
Contrary to these and various other studies, AZT + IDV did not induce apoptosis at 
therapeutic concentrations in primary human umbilical cells and various other studies 
(Jiang et al., 2007). In addition to this, an emerging body of literature suggests that 
protease inhibitors may also be anti-apoptotic by inhibiting calpain (Lichtner et al., 
2006). In view of this conflicting research, we tested whether AZT + IDV can induce 
apoptosis in hCMEC/D3 cells. Cytchrome c and procaspase 3 levels were elevated in 
cytosolic fractions of the treated groups when compared to those of the control groups. 
To further ascertain that AZT + IDV treatment induced apoptosis, cells stained with an 
AO/EB mixture were observed under a fluorescent microscope. Treated cells showed 
changes in cellular morphology, including chromatin condensation, membrane blebbing, 
and fragmented nuclei and apoptotic bodies. Results from both studies provided sufficient 
support that AZT + IDV treated hCMEC/D3 cells were undergoing programmed cell 
death. 
          Apoptosis can be triggered by many different stimuli, including engagement of 
death receptors by cytokines (such as TNF-alpha and Fas ligand), toxins, and oxidative 
stress. Early events in apoptosis include the release of cytochrome c (from mitochondria) 
and calcium from endoplasmic reticulum in to the cytosol, which are necessary for 
apoptosis.  A small amount of cytochrome c released from mitochondria can bind to and 
promote calcium conductance through inositol-1,4,5–triphosphate (InsP3) receptors in the 
endoplasmic reticulum membrane. The released calcium then triggers a massive exodus 
of cytochrome c from all mitochondria in the cell, thereby activating the caspases and 
nuclease enzymes that finalize the apoptotic process (Boehning et al., 2003). Evidently, 
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calcium uptake into the mitochondria is secondary to an increase in the cytoplasmic 
calcium concentration as a stimulus for the massive release of cytochrome c.  Results 
from our studies show that a calcium based mechanism may be involved in the extensive 
release of cytochrome c and the execution of cell death induced by an AZT + IDV 
combination in blood-brain vascular endothelial cells.              
           A noticeable decrease in trans-endothelial electrical resistance (TEER) and an 
increase in dextran permeability across the monolayer of endothelial cells provide 
evidence that HAART drugs induce gaps between endothelial cells. This is in agreement 
with results reported from previous studies (Fiala et al., 2000). Inflammatory mediators 
(histamine and thrombin) tend to increase centripetal tension and intercellular and matrix 
adhesion in the absence of a rise in cyclic adenine monophosphate.  Thrombin triggers 
multiple signal pathways through activation of G proteins which can, in turn, activate 
phospholipase C. Activation leads to a series of signaling cascades, ultimately leading to 
protein kinase C activation. These signals lead to activation of multiple protein kinases 
and phosphorlyation of their target proteins, filamin, myosin light chain kinase (MLCK), 
and tight junction (TJ) proteins (Sansdoval et al., 2001). Phosphorylation of these target 
proteins induces interendothelial gaps and monocyte migration across the BBB models 
(Bogatcheve et al., 2002). Our data concurs with a previous study on endothelial cells, 
which showed that HAART drugs can induce gaps between endothelial cells. 
            Glutathione (L-γ-glutamyl-L-cysteinylglycine, GSH) is the most prevalent intra-
cellular thiol in mammals. It is known to be involved either directly or indirectly in a 
number of biological phenomena, including protecting cells from harmful reactive 
oxygen intermediates (ROI), and acting as a coenzyme in several enzyme catalyzed 
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reactions. Although GSH by itself is poorly absorbed through cells and has high affinity 
for oxidation, various analogues of cysteine and GSH have been synthesized known to 
easily permeate cell. One such kind of analogue known to pass BBB and increase GSH 
levels is N-acetylcysteine amide (NACA).  Although cytotoxicity in AZT+IDV treated 
cells was abolished, a slight increase in viability was observed in cells pretreated with 
NACA. 
            In order to comprehend the results, and further establish the antioxidant effects of 
NACA, the ROS levels in treated cells were evaluated. NACA completely decreased the 
ROS levels in the AZT+IDV treated group. These results agree with data reported from 
previous other studies, where NACA successfully inhibited the increase in free radicals 
(Penugonda et al., 2005) NACA is thought to increase GSH levels in cells, both by 
providing the important GSH precursor cysteine, and by reducing GSSG back to GSH by 
thiol disulfide exchange (Grinberg et al., 2005).  According to figure 4.20 NACA 
appears, to replenish GSH levels, which may be useful in reversing some of deleterious 
effect of oxidative insults. 
                The ability of NACA to scavenge ROS and increase GSH levels without a 
significant effect on cell viability, as seen in our studies, has also been reported in 
previously reported studies of NACA (Rong et al., 2009). Moreover cells were only 
preinucbated with NACA in our studies for only 1 hr prior to 72 hr exposure with 
AZT+IDV. Further research needs to be done to develop an effective dosing protocol to 
efficiently establish the effects of NACA.  
            In summary, our results demonstrate that the HAART drug combination of AZT + 
IDV can induce cytotoxicity and alter the blood-brain endothelial cell functions.  
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Alteration of the endothelial functions is due to increased oxidative stress and lipid 
peroxidation. Our results also suggest that treatment with AZT + IDV leads to 
depolarization of membrane potential and energy loss, ultimately causing mitochondrial 
dysfunction. Furthermore, treated cells undergoing apoptosis and elevated intracellular 
calcium mediated the drug-induced apoptosis in our current study. Thus, treatment with 
HAART drug combinations may have to be used with caution in HIV-infected patients, 
although inclusion of antioxidants like NACA in HAART therapy may protect patients 
with HIV-1 associated neurocognitive disorders from drug-induced toxicity. 
6.2. IN VIVO RESULTS 
            Vascular function is as essential as the heart beat, since it regulates blood pressure 
and thereby protects from hypertension and atherosclerosis in the long term. In addition, 
it maintains the function of the vessel walls as a blood-barrier in the brain and thereby 
prevents leukocyte infiltration as well as inflammatory processes in the vascular wall. 
Blood-brain barrier disruption has been implicated in numerous neurocognitive disorders. 
The role of HAART drugs in BBB disruption and the mechanism involved in this 
disruption is poorly understood in HAND. Our previous in vitro study with HAART 
drugs proved that AZT + IDV induced toxicity through an oxidative stress mediated 
mechanism in cell model of the BBB. Pretreatment with NACA abrogated some of the 
effects due to drug exposure in in vitro study. In addidition,  an in vivo study was 
conducted  to further understand the mechanism and  implicate the oxidative stress role of 
HAART drugs in BBB disruption, and also to establish the protective role of thiol 
antioxidant NACA to protect against oxidative stress in HIV transgenic animals treated 
with HAART drugs.  
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             Initially to elucidate the oxidative stress effect of viral proteins and antiretroviral 
drugs in the BBB and brain, GSH levels were measured in BBB microvessels as well as 
in the brain (Table 5.1).  In the literature, a decrease in GSH levels has been connected to 
physiological processes such as aging and neurological disorders like schizophrenia, 
Alzheimer's disease, and epilepsy (Do et al., 2000; Gu et al., 1998; Mueller et al., 2001). 
Previous studies from our lab have reported that animals exposed to HIV viral proteins 
(gp120+Tat) had significant decreases in GSH levels in their brains as compared to 
controls. In our study we report similar results in the brain as well as the BBB, which 
indicate that viral proteins decrease GSH (Banerjee et al., 2010).  The decrease in GSH is 
attributed to increase in oxidative stress in cell culture and in in vivo settings as well. 
Along with that, treatment with ART drugs also decrease GSH in the BBB and the brain. 
This result advocates our findings obtained in BBB cell model. NACA treatment in these 
animals replenished the thiol levels in both HIV and HIV+ART group. Decreased GSH 
may increase the susceptibility to free radical attack of cellular proteins and lipids 
resulting in MDA, an end product of lipid peroxidation. Our results in both the HIV and 
HIV group treated with ART drugs show an increase in MDA levels. Pretreatment with 
NACA decreased the levels of MDA in both the HIV and HIV+ART groups. 
            Various effects of HIV neuropathology in HAART-medicated patients have been 
reported, including severe white matter injury, extensive perivascular lymphocytic 
infiltration, and Aβ accumulation of AD-like lesions (Gray et al., 2003, 2005; Greene et 
al., 2005). Recent studies suggest that HAND prevalence is actually rising as the number 
of treated subjects with chronic HIV infection increases, despite HAART medication (Xu 
et al., 2009). Consequently, considering the link between chronic neuroinflammation, 
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neuronal/ synaptodenritic degeneration and Alzheimers disease, neuroinflammation is 
likely to play an important role in the pathogenesis of HAND by the killing of neurons 
through inflammatory mechanisms. ROS play a key role in inflammatory tissue 
destruction. The phagocyte NADPH oxidase is the best studied ROS-generating system. 
In the central nervous system, it is expressed in microglia in the brain and to a lesser 
extent in neurons. Indeed, there is emerging experimental evidence for a role of NADPH 
oxidase in Alzheimer's and cerebrovascular disease. Recently, six novel ROS-generating 
NADPH oxidases have been discovered (Sankarpandi et al., 1998; Bianca et al., 1999). 
Several of them are also expressed in the central nervous system. In this current study, we 
hypothesize a role of NADPH oxidases in neurocognitive disorders in HAART treated 
patients. 
            In addition to mitochondrial sources of ROS, O2·–can be derived from xanthine 
oxidase, NADPH oxidases, cyclooxygenases, lipoxygenases and uncoupled nitric oxide 
synthase. On the basis of experimental and clinical studies it has been proposed that 
NADPH oxidase is the predominant, O2·– producing enzyme in the context of oxidative 
stress. NADPH oxidase activation has also been implicated in loss of neuronal coupling.   
            According to figure 5.1 NADPH oxidase activities in both the HIV and ART- 
treated group appear to be elevated, with the latter showing a higher activity than former 
HIV group. To best of our knowledge we are the first to report the increase in NADPH 
oxidase activity in brain samples of ART treated HIV transgenic animals. NADPH 
oxidase activation has been also implicated in disruption of blood brain barrier following 
stroke and in apoptosis (Kahles et al., 2007). Administration of NACA appears to have 
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alleviated some of the NADPH oxidase activity. Although the specific inhibitory 
mechanism involved cannot be explained at this juncture.  
           Activation of NADPH oxidase enzyme results in transport of electrons from 
NADPH to molecular oxygen resulting in formation of superoxide. In order to support 
our earlier assumption and results of NADPH oxidase activation, we measured the 
superoxide levels. Although the HIV treated group did not show any increase in O2·– 
when compared to control, ART treated HIV group showed a massive increase in O2·– 
levels.  Studies with ritonavir showed an increased NADPH oxidase activity in porcine 
arteries (Chai et al., 2005).  Wang et al have shown that superoxide anion is significantly 
increased in porcine coronory arteries treated with ritonavir and amprenavir. 
Furthermore, they showed that indinavir and AZT- treated porcine arteries also had a 
significant increase in superoxide levels when compared to control (Wang et al., 2009; 
Jiang et al., 2010). Treatment with NACA decreased the superoxide levels in the ART 
treated HIV group (Figure 5.2). This effect can be explained based on the thiol group (-
SH) group in NACA. Thiols react with free radicals by quenching the free radicals and, 
in turn losing proton forming thiyl radicals, which undergo a self-quenching process by 
forming a disulfide bond. 
             NADPH oxidase-derived superoxide reacts with NO.  to form peroxynitrite 
(ONOO-) that is toxic. The highly reactive peroxynitrite has been implicated in the death 
of cultured neurons and oligodendrocyte progenitors (Scott et al., 2003).  Tyrosine 
nitration, a marker of ONOO- activity, has been correlated with tissue damages in human 
neuropathologies such as multiple sclerosis, ALS, and Parkinson’s and Alzheimer’s 
diseases, as well as in animal models of these diseases, including LPS-triggered 
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neuroinflammation (Cheret et al., 2008). Our results (shown in Figure 5.3) indicate an 
increase in the levels of nitrite formation in ART treated HIV group as a result of higher 
superoxide levels generation mediated by NADPH oxidase.  It is also interesting that the 
ART treated group had a greater increase in nitrite levels when compared HIV groups 
indicating that ART may be potentiating NADPH oxidase activity in HIV transgenic 
animals. Treatment with NACA significantly reduced the nitrite levels in ART +HIV 
group.  Peroxynitrite reacts with the thiol group producing the unstable sulphenic acid, 
which in turn reacts with another thiol yielding the disulphide by a two electron oxidation 
pathway. One-electron oxidation pathway is also believed involved in reducing 
peroxynitrite levels. Peroxynitrous acid, or a secondary species derived from it, reacts 
with the thiol producing the thiyl radical. The latter can dimerize to the disulphide, or can 
react with oxygen to produce the peroxyl radical or with the thiolate yielding the 
disulphide radical anion (Quijano et al., 1997). 
            A proposed convergent mechanism based upon our in vitro and in vivo results, 
involved in blood-brain endothelial dysfunction as illustrated in Figure 6.1.  HAART 
drugs may induce oxidative stress and mitochondrial dysfunction by increasing reactive 
oxygen species. These ROS may, in turn cause a decrease in GSH and increase in an 
MDA levels.  Changes in these parameters may also result in apoptosis and endothelial 
dysfunction. It is also possible that HAART drugs may activate NADPH oxidase enzyme, 
thereby increasing superoxide production, which, in turn may lead to peroxynitrite radical 
generation. Nitration of proteins and enzymes by ONOO-   may lead to further deleterious 
signaling cascade, resulting in BBB endothelial dysfunction and neurodegeneration in the 





         
 Figure 6.1. Schematic illustration of proposed mechanism for BBB dysfunction.    







                                                    7. CONCLUSION 
            HIV-1 associated neurocognitive disorders are a still a significant health concern 
in HIV patients treated with antiretroviral therapy. Although HAART treatment has 
resulted in decreased mortality, the negative impact of therapy resulted in endothelial 
dysfunction related disorders like cardiovascular diseases. However, their effect on BBB 
and brain has not been studied in relation to neurocognitive disorders. Our study 
attempted to evaluate the effect of an antiretroviral drug combination of AZT and IDV on 
the BBB and brain. 
            Findings from our in vitro studies with HAART drugs (AZT+IDV) indicate that 
prolonged use of antiretroviral drugs may alter the function of the BBB.  These potential 
toxic effects appear to be manifested through the dysfunction of the mitochondria and 
increase in oxidative stress.  Our results from in vivo studies demonstrate that an alternate 
pathway involving reactive nitrogen species (RNS) may take part in signaling cascade of 
BBB disruption and neuronal degeneration in the brain. The protective effects of NACA 
were also shown in reducing the oxidative stress mediated effects of the AZT and IDV 
combination.  The antioxidant effects of NACA against RNS were also prominent in 
ART -treated HIV transgenic rats.  The increases in oxidative stress and NADPH oxidase 
activity in the BBB and brain is of particular concern in ART- treated groups and may 
signify their ability to potentiate the degenerative effect of viral proteins. No 
neurodegenerative markers were studied in this part of research, so the role of ART drugs 
in HAND is still unclear and needs further in depth investigation. The inclusion of thiol 
antioxidants like NACA, with the ability to cross the BBB, may prove beneficial in 
delaying or inhibiting some of the symptoms of neurocognitive disorder.  
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